VOLUME 4
ISSUE 3
Fall 2025

ISSN 2816-5152 (PRINT)
ISSN 2816-5160 (ONLINE)

Canadian Hematology Today

Editorial Board

Peter Anglin, MD, FRCPC, MBA

Physician Lead
Stronach Regional Cancer Centre and Central LHIN Regional Cancer Program

Laurie H. Sehn, MD, MPH

Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia

Julie Stakiw, MD, FRCPC

Medical Director, Oncology
Clinical Professor Hematological Oncology
University of Saskatchewan

Darrell White, MD, MSC, FRCPC, FACP

Professor of Medicine
Senior Associate Dean
Faculty of Medicine, Dalhousie University

Table of Contents

Canadian Hematology Today is published 3 times per year in English and French.

To contribute to a future issue, email us at info@catalytichealth.com. Submission guidelines and editorial policies are available on the journal website, **canadianhematologytoday.com**.

To subscribe to Canadian Hematology Today and more open access scientific specialty journals published by Catalytic Health, please visit **catalytichealth.com/cht**.

The content of this journal qualifies for Section 2 (self-learning) CPD credits under the Royal College's Maintenance of Certification (MOC) program. For more information on how journal articles can meet your CPD needs, please consult the Royal College's website. For more personalized support, please contact the Royal College Services Centre (1-800-461-9598) or your local CPD Educator.

Pr imbruvica® (ibrutinib) + venetoclax

The first and only **all-oral, fixed-duration** treatment regimen indicated in adult patients with previously untreated chronic lymphocytic leukemia (CLL)*,†,1,2

IMBRUVICA® (ibrutinib) is indicated in combination with venetoclax for the treatment of adult patients with previously untreated CLL, including those with 17p deletion.[1]

* In patients with previously untreated CLL, IMBRUVICA® can be used in combination with venetoclax for a fixed duration of treatment. IMBRUVICA® should be administered as a single agent for 3 cycles (1 cycle is 28 days), followed by 12 cycles of IMBRUVICA® plus venetoclax, starting at Cycle 4. Venetoclax should be given as per the venetoclax Product Monograph.

Now covered in: AB, BC, NB, NL, NS, ON, QC‡, SK & NIHB
(criteria apply; EAP criteria apply in ON; not yet reimbursed elsewhere)[3-11]
Refer to each provincial formulary or reimbursement body for full coverage criteria details.

Safety Information[1]

Clinical use:

Pediatrics (<18 years of age): Not authorized for pediatric use for indication presented in this advertisement. See Product Monograph for complete list of indications and associated clinical use.

Geriatrics (≥65 years of age): No overall differences in efficacy were observed between patients with B-cell malignancies ≥65 years of age and younger patients. Grade ≥3 AEs, SAEs, fatal AEs, and AEs leading to drug discontinuation occurred more frequently among elderly patients than younger ones.

Most serious warnings and precautions:

Bleeding events: Risk of major bleeding events (Grade ≥3), some fatal, including intracranial hemorrhage (subdural hematoma, cerebral hemorrhage, subarachnoid hemorrhage), gastrointestinal bleeding, hematuria, and post-procedural hemorrhage.

Hepatic impairment: Dose reductions or avoidance of IMBRUVICA® should be considered for patients with hepatic impairment. Cases of hepatotoxicity, and hepatic failure, including fatal events, have been reported. Assess liver function status before initiating treatment and periodically monitor for changes in liver function parameters during treatment.

Cardiac arrhythmias and cardiac failure: Fatal and serious cardiac arrhythmias or cardiac failure have been reported; patients with significant cardiac co-morbidities may be at greater risk of events, including sudden fatal cardiac events.

Other relevant warnings and precautions:

- Second primary malignancies
- Cardiovascular risks, including PR interval prolongation, hypertension, and cerebrovascular accidents
- Driving and operating machinery
- Drug interactions. Strong CYP3A inhibitors should be avoided
- Tumour lysis syndrome
- Diarrhea
- Hematologic risks, including cytopenias, lymphocytosis, and leukostasis
- Hemorrhagic events
- Immune system risks, including infections, progressive multifocal leukoencephalopathy, and hepatitis B reactivation
- Monitoring and laboratory tests
- Peri-operative considerations
- Renal impairment
- Female and male reproductive health, including fertility and teratogenic risk
- Interstitial lung disease
- Should not be used during pregnancy
- Do not breastfeed while receiving IMBRUVICA®

For more information:

Consult the Product Monograph at innovativemedicine.jnj.com/canada/our-medicines for information regarding indications, adverse reactions, interactions, and dosing which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-567-3331.

AE = adverse event; EAP = Exceptional Access Program; ECOG = Eastern Cooperative Oncology Group; NIHB = Non-Insured Health Benefits; SAE = serious adverse event

† Comparative clinical significance unknown.

‡ As monotherapy during three cycles, then in association with venetoclax, for first-line treatment of symptomatic CLL in persons whose ECOG performance status is ≤ 2; The first authorization is given for a maximum duration of six cycles of 28 days. Subsequent authorization is given for a duration of nine cycles, for a total of 15 cycles; When requesting continuation of treatment, the physician must provide evidence of a beneficial clinical effect by the absence of disease progression.[10]

References: 1. IMBRUVICA® Product Monograph, Janssen Inc., March 20, 2025. **2.** Data on file. Janssen Inc., 2023. **3.** Alberta Health Services. Outpatient Cancer Drug Benefit Program. August 27, 2025. https://www.albertahealthservices.ca/assets/programs/ps-1025651-drug-benefit-list.pdf. Accessed September 19, 2025. **4.** BC Cancer Benefit Drug List. July 2025. http://www.bccancer.bc.ca/systemic-therapy-site/Documents/Policy%20and%20Forms/Benefit%20Drug%20List.pdf. Accessed September 19, 2025. **5.** New Brunswick Drug Plans. Bulletin #1160. June 23, 2025. https://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrugPlan/FormularyUpdates/nb-drug-plans-bulletin-1160.pdf. June 23, 2025. Accessed September 19, 2025. **6.** Non-Insured Health Benefits (NIHB) First Nations and Inuit Health Branch. Drug Benefit List. Indigenous Services Canada. July 17, 2025. https://nihb-ssna.express-scripts.ca/en/0205140506092019/16/160407. Accessed September 19, 2025. **7.** Newfoundland and Labrador Prescription Drug Program. https://www.gov.nl.ca/hcs/files/Criteria-Jun-2025.pdf. June 13, 2025. Accessed September 19, 2025. **8.** Pharmacare News Bulletins. Nova Scotia Pharmacare. May 1, 2025. https://novascotia.ca/dhw/pharmacare/pharmacists_bulletins/pharmacists-bulletin-25-07.pdf. Accessed September 19, 2025. **9.** Cancer Care Ontario. Drug Formulary: Ibrutinib. August 2025. https://www.cancercareontario.ca/en/drugformulary. Accessed September 19, 2025. **10.** RAMQ (Official Mark of the Régie de l'assurance maladie du Québec). Formulary Update. August 14, 2025. Available at: https://www.ramq.gouv.qc.ca/en/about-us/list-medications. Accessed September 19, 2025. **11.** Saskatchewan Cancer Agency Drug Formulary. Saskatchewan Cancer Agency. September 1, 2025. https://saskcancer.ca/sites/default/files/2025-04/SCA%20Drug%20Formulary%20-%202025-05-01.pdf. Accessed September 19, 2025.

Johnson & Johnson | 19 Green Belt Drive | Toronto, Ontario | M3C 1L9
innovativemedicine.jnj.com/canada | CP-514803E

For more information, contact your Johnson & Johnson sales representative.

Pr imbruvica® (ibrutinib)

pharmacyclics® An AbbVie Company

MEMBER OF INNOVATIVE MEDICINES CANADA

REVIEWED BY PAAB

Johnson&Johnson | Oncology

About the Authors

Jowon L. Kim, MD

Dr. Kim is a lymphoma fellow at Mayo Clinic Rochester. She obtained her medical degree and completed Internal Medicine and Hematology training at the University of British Columbia. Her clinical research focus is in Hodgkin lymphoma, with an interest in further refining risk groups to guide optimal treatment selection in the era of novel therapies.

Affiliations: Division of Hematology, University of British Columbia, Vancouver, B.C.

Kerry J. Savage, MD

Dr. Kerry Savage is a Medical Oncologist at BC Cancer and a Professor of Medicine (tenure track) at the University of British Columbia (UBC). She received a BSc (Biology (Genetics) and a M.D. from UBC. She completed a post-doctoral research fellowship in lymphoma at the Dana-Farber Cancer Institute in Boston, MA, and earned a MSc in Epidemiology from the Harvard School of Public Health. She is the Business Unit Leader for the lymphoma/myeloma and melanoma BC Cancer Vancouver clinical trial group. She is on the Scientific Advisory Board for the Lymphoma Research Foundation and Lymphoma Canada. She is currently an Associate Editor at Haematologica. Dr. Savage's research interest areas include peripheral T-cell lymphomas, Hodgkin lymphoma and primary mediastinal large B-cell lymphoma including research in the AYA age group, as well as investigating predictors of central nervous system relapse in diffuse large B-cell lymphoma.

Affiliations: Centre for Lymphoid Cancer and Division of Medical Oncology, BC Cancer, Vancouver, B.C.

doi.org/10.58931/cht.2025.4377

New Developments in the Front-line Treatment of Advanced Stage Classic Hodgkin Lymphoma: A Canadian Perspective

Jowon L. Kim, MD
Kerry J. Savage, MD

Introduction

Classic Hodgkin lymphoma (cHL) is highly curable, with excellent outcomes achieved through decades of treatment refinement. Recent years have witnessed a paradigm shift in the management of patients with advanced stage disease, driven by the integration of novel therapies into front-line treatment. Minimizing long-term complications remains an important objective, especially for patients in the adolescent/young adult (AYA) age group. Herein, we summarize the latest developments in the treatment of advanced stage cHL through a Canadian lens, focusing on recent clinical trials that have reshaped the therapeutic landscape.

Definition of Advanced Stage in cHL

The definition of advanced stage has varied widely across guidelines and clinical trials worldwide, with potential downstream funding implications. The National Comprehensive Cancer Network (NCCN) and European Organization for Research and Treatment of Cancer (EORTC) define advanced stage as stage 3–4, while the German Hodgkin Study Group (GHSG) also includes stage 2B with risk factors (large mediastinal mass >0.33 of the maximum transverse thoracic diameter on chest X-ray [CXR] and/or extranodal disease) (**Table 1**). In the RATHL study, advanced stage also included high-risk stage 2, defined as stage 2B or 2A with adverse features (bulky disease >0.33 of transthoracic diameter or >10 cm elsewhere; ≥3 involved nodal sites).[1] Similarly, the Children's Oncology Group (COG) AHOD1331 Phase 3 trial evaluated upfront brentuximab vedotin (BV-AVEPC) with ABVEPC (doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide) in patients aged 2–21 years with advanced stage disease, and included stage 2B with large mediastinal mass (>0.33 of the maximum transverse thoracic diameter on CXR or continuous nodal aggregate >6 cm in other sites), but excluded stage 3A.[2] Finally, at BC Cancer, we define advanced stage as 2B, 3, 4, and stage 1 or 2 with bulky mass (≥10 cm in any dimension) or disease determined to be too extensive to encompass in a radiotherapy field.

Evolution of Treatment Strategies for Advanced Stage cHL: From ABVD to PET-adapted Approaches

For many years, the standard front-line therapy for advanced stage cHL was the ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine). ABVD has demonstrated high efficacy, with cure rates approaching 80%, though failure can occur in 20–30% of patients, and bleomycin-associated pneumonitis remains a concern.[1,3-9] Dose intensive escBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) has demonstrated improved progression-free survival (PFS) but not overall survival (OS) compared with ABVD, and is associated with long-term toxicity, including secondary malignancies and infertility.[3,4] Early studies with positron emission tomography (PET) scanning suggested that those with a PET2-positive scan have poor outcomes (PFS: 13–28%) if ABVD is continued.[8,10] Thus, several PET-adapted studies have investigated dose escalation (i.e., to escBEACOPP) if PET2-positive[1,11,12] and de-escalation (omission

	EORTC/LYSA	GHSG	COG	NCCN	RATHL	BC Cancer
Early/limited stage						
Risk factors	Large mediastinal mass[a], age ≥50 years, elevated ESR (>50 mm/h without B symptoms, >30 mm/h with B symptoms, involvement of ≥4 supradiaphragmatic nodal areas	Large mediastinal mass[b], extranodal disease, elevated ESR (>50 mm/h without B symptoms, >30 mm/h with B symptoms), involvement of ≥3 nodal areas on both sides of the diaphragm		Bulky disease[d], elevated ESR ≥50 mm/h, B symptoms, involvement of ≥4 nodal sites	Bulky disease[d], ≥3 nodal sites	
Early favourable	Stage 1–2 without risk factors	Stage 1-2 without risk factors	Stage 1A, 2A	Stage 1–2 without risk factors		
Early unfavourable	Stage 1–2 with ≥1 risk factor	Stage 1-2A with ≥1 risk factor, 2B with elevated ESR or ≥3 nodal areas or both	Stage 1A/ 2A with bulky disease[c] ± extranodal disease (E), 1B/2B±E,3A±bulky±E	Stage 1–2 with ≥1 risk factor		
Limited stage						Stage 1, 2A, non-bulky (<10cm)
Advanced stage						
Advanced	Stage 3–4	Stage 2B with large mediastinal mass and/or extranodal disease Stage 3–4	Stage 2B bulky[c] Stage 3B, 4	Stage 3–4	Stage 2A with risk factors Stage 2B Stage 3–4	Stage 2B Bulky mass[e] (≥10 cm) Stage 3–4

Table 1. Definitions of risk and stage groups in clinical trials and practice guidelines in cHL; *courtesy of Jowon L. Kim, MD and Kerry J. Savage, MD.*

B symptoms: fever, drenching night sweats, unexplained weight loss >10% of baseline body weight over 6 months.

Abbreviations: cHL: classic Hodgkin lymphoma; **COG:** Children's Oncology Group; **ESR:** erythrocyte sedimentation rate; **EORTC:** European Organization for Research and Treatment of Cancer; **GHSG:** German Hodgkin Study Group; **LYSA:** Lymphoma Study Association; **NCCN:** National Comprehensive Cancer Network; **RATHL:** Risk-adapted therapy in Hodgkin lymphoma.[1]

a: mediastinum to thoracic ratio >0.35;
b: mediastinum to thoracic ratio >0.33;
c: mediastinal mass >0.33 thoracic diameter, extramediastinal nodal aggregate >6 cm in longest transverse diameter;
d: mediastinum to thoracic ratio >0.33 or >10 cm elsewhere;
e: also includes rare stage 1 with bulky mass.

catalytic health

medical minds meet here

Medical minds gather here.

As the largest independent medical publisher in Canada, our peer-reviewed open access scientific journals are a practical resource for Canadian healthcare practitioners. We currently publish specialty journals in the areas of allergy & immunology, dermatology, hematology, ophthalmology, diabetes & endocrinology, gastroenterology, primary care, women's health, rheumatology, oncology, respirology and our press is constantly growing with new titles planned.











of bleomycin from ABVD[1] and omission of consolidative radiotherapy (RT) in those with bulky disease[13-16]) if PET2-negative. An alternate approach is to start with escBEACOPP and de-escalate to ABVD if PET2-negative (AHL2011 study; **Table 2**).[17] Since the RATHL study demonstrated comparable PFS with PET2-guided omission of bleomycin[1], this practice has been widely adopted globally. Although subsequent studies (mostly real-world analyses) have demonstrated a higher 2–5 year PFS of 38–64% in PET2-positive patients who continued on ABVD[18-21], PET2-guided dose escalation to escBEACOPP appears to result in a higher PFS of 60-66% (with limitations of cross-trial comparison), but with similar OS.[11,12,22] Thus, with uncertainty of benefit and toxicity concerns with escBEACOPP, practices vary. With the brentuximab vedotin containing alternate BrECADD demonstrating improved efficacy and safety (**Table 3**), use of escBEACOPP will likely diminish.

Integration of Novel Agents in the Front-line Treatment of Advanced Stage cHL

Brentuximab Vedotin (BV)-AVD and Other BV-containing Front-line Regimens

Brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30, initially demonstrated efficacy in a pivotal Phase 2 trial in patients with relapsed/refractory cHL after autologous stem cell transplant, with an overall response rate (ORR) of 75% and a complete response (CR) rate of 34%.[27] The ECHELON-1 trial compared BV-AVD (BV, doxorubicin, vinblastine, and dacarbazine) to ABVD in patients ≥18 years with stage 3–4 cHL.[7] The modified PFS, which included use of subsequent therapy for incomplete response (defined as Deauville [D] score 3–5) by blinded review, was superior for BV-AVD (2-year modified PFS: 82.1% vs. 77.2%; hazard ratio [HR]: 0.77, 95% confidence interval [CI]: 0.6–0.98).[24] However, in subgroup analysis, benefit was confined to those with stage 4 disease only, which led to initial approval restricted to stage 4 by Health Canada and the European Medicines Agency (EMA). However, with longer follow-up, 5-year PFS benefit was observed in stage 3 and 4 (82.2% vs. 75.3%; HR: 0.68, 95% CI: 0.53–0.87)[18], and subsequent 6-year OS benefit was demonstrated in the intention-to-treat population (93.9% vs. 89.4%; HR: 0.59, 95% CI: 0.40-0.88).[7] This resulted in expanded approval to stage 3 by the EMA in October 2023 and endorsement by Canada's Drug Agency (CDA) in September 2024. Simultaneously, the pediatric regimen BV-AVEPC was CDA endorsed in those aged 2–21 years.[2]

Other upfront BV-containing regimens have demonstrated significant benefit in patients with high-risk stage 2 disease (**Table 2**). The landmark GHSG Phase 3 HD21 trial compared BrECADD (BV, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) and escBEACOPP in patients with advanced stage cHL aged 18–60 years, with two co-primary endpoints (superiority in safety/treatment-related morbidity, and non-inferiority in efficacy/PFS).[26] The omission of vincristine allowed for a higher dose of BV (1.8 mg/kg) in this regimen compared to BV-AVD (1.2 mg/kg). Following results from HD18, a trial amendment introduced PET2-guided treatment, with patients receiving 4 cycles if PET2-negative (D1-3) vs. 6 cycles if PET2-positive (D4-5). PET2-negative status was lower than in other trials (64%), which may highlight a greater frequency of false positives with this regimen. Consolidative RT was recommended in those with end-of-treatment (EOT) PET-positive residual disease and administered in 15% of the escBEACOPP group and 14% of the BrECADD group. BrECADD demonstrated significantly lower treatment-related morbidity (42% vs. 59%; p<0.0001), driven mostly by reduced hematologic toxicity. Although the study was designed to demonstrate non-inferiority for PFS, a superior 4-year PFS was demonstrated (94.3% vs. 90.9%; p=0.035), with similar OS (98.6% vs. 98.2%). Notably, patients <40 years of age derived the greatest benefit (HR: 0.53) from BrECADD, as did those with stage 2 disease (HR: 0.35), which was likely the predominant stage in this younger age group. Study follow-up remains short to evaluate for long-term complications; however, gonadal function recovery by follicle-stimulating hormone levels was observed in 95% of patients with BrECADD vs. 72.5% with escBEACOPP in women and 86% vs. 39% in men, respectively. Successful childbirths were observed, with 62 births among 59 couples with BrECADD, and 46 births among 40 couples with escBEACOPP. BRECADD is currently under CDA review.

The pediatric trial AHOD1331 included patients aged 2–21 years with "high-risk" cHL (**Table 2**), who were randomized to 5 cycles of BV-AVEPC (BV replacing bleomycin) or

Trial	Advanced stage definition	Treatment arms	Median follow-up	PFS	OS	Comment
PET2-adapted studies						
RATHL[1,22] n=1,201	Stage 2B-4, 2A with risk factors Age 18–79y	After 2ABVD: PET2-neg (D1–3): 4ABVD vs. 4AVD PET2-pos (D4–5): BEACOPP#	3.4y, 7.3y	**All:** 7y PFS 78.2% **PET2-neg:** • 3y PFS 85.7% with ABVD vs. 84.4% with AVD • 7y PFS 81% with ABVD vs. 79.2% with AVD **PET2-pos:** • 3y PFS 67.5% • 7y PFS 65.9%	**All:** 7y OS 91.6% **PET2-neg:** • 3y OS 97.2% with ABVD vs. 97.6% with AVD • 7y OS 93.2% with ABVD vs. 93.5% with AVD **PET2-pos:** • 3y OS 87.8% • 7y OS 83.2%	Led to widespread practice of dropping bleomycin if PET2-neg post ABVD. The practice of PET2-guided dose escalation to BEACOPP varies.
GITIL/FIL HD0607[11,14] n=782	Stage 2B–4 Age 18–60y	After 2ABVD: PET2-neg (D1-3): 4ABVD PET2-pos (D4-5): 4escBEACOPP (+/- R)	3.6y, 5.9y	**All:** 3y PFS 82% **PET2-neg:** • 3y PFS 87% • Bulky (>5 cm) with PET2/EOT PET-neg scan randomized to RT vs. no RT: 6y PFS 92% with RT vs. 90% without RT (p=0.48) **PET2-pos:** • 3y PFS 60% (vs. PET2-neg, p<0.001) • By D score, 3y PFS 73% with D4 vs. 35% with D5 (p<0.001)	**All:** 3y OS 82% **PET2-neg:** • 3y OS 99% • Bulky (>5cm) with PET2/EOT PET-neg scan randomized to RT vs. no RT: 6y OS 99% with RT vs. 98% without RT (p=0.61) **PET2-pos:** • 3y OS 89%	Established that consolidative RT can be omitted in patients with bulky disease (>5 cm) treated with ABVD if PET2 and EOT PET-neg. Subset with 'classic' bulky >10 cm also showed no impact of omission of RT (6y PFS: 89% vs. 86%, p=0.53).
AHL 2011[17,23] n=823	Stage 2B with large mediastinal mass (>33% maximal thoracic diameter), 2BE, 3, 4 Age 16-60y	After 2escBEACOPP: PET2-neg (D1-3): 4escBEACOPP vs. 4ABVD PET2-pos (D4-5): 4escBEACOPP	4.2y, 5.6y	**PET2-neg:** • 5y PFS 87.5% with 6escBEACOPP vs. 86.7% with 2escBEACOPP + 4ABVD (p=0.67) **PET2-pos:** • 5y PFS: 68.2%	**PET2-neg:** • 5y OS 97.7% in both arms, p=0.53 **PET2-pos:** • 5y OS: 92%	Led to practice of starting therapy with escBEACOPP for 2 cycles and de-escalation to ABVD if PET2-neg in some centres.
Trials incorporating frontline brentuximab vedotin or nivolumab						
ECHELON-1[7,24] n=1,334	Stage 3–4 cHL Age ≥18y	6 cycles of BV-AVD vs. ABVD	2.1y, 6.1y	**All:** • 2y modified PFS 82.1% with BV-AVD vs. 77.2% with ABVD (HR: 0.77, 95% CI: 0.6-0.98) • 6y PFS 82.3% with BV-AVD vs. 74.5% with ABVD (HR: 0.68, 95% CI: 0.53-0.86)	**All:** • 2y OS 96.6% with BV-AVD vs. 94.2% with ABVD (HR: 0.73, 95% CI: 0.45-1.18) • 6y OS 93.9% with BV-AVD vs. 89.4% with ABVD (HR: 0.59, 95% CI: 0.4-0.88)	BV-AVD Health Canada approved in 2017 for stage 4 (CDA endorsed 2020). CDA endorsed for stage 3 in 2024.

Trial	Advanced stage definition	Treatment arms	Median follow-up	PFS	OS	Comment
GHSG HD21[26] n=1,500	Stage 3–4, 2B with risk factors (large mediastinal mass ≥1/3 maximal thoracic diameter, 2BE) Age 18–60y	4–6 cycles of BrECADD vs. escBEACOPP PET2-adapted, 4 cycles if PET2-neg and 6 cycles with PET2-pos (D4-5)	4y	**All:** 4y PFS 94.3% with BrECADD vs. 90.9% with escBEACOPP; p=0.035	**All:** 4y OS 98.6% with BrECADD vs. 98.2% with escBEACOPP	BrECADD improved treatment-related morbidity. Greatest PFS benefit in patients <40y (HR: 0.53) and high-risk stage 2B (HR: 0.35). BrECADD currently under CDA review.
AHOD1331[2] n=587	Stage 2B with risk factors (bulky mediastinal mass >1/3 thoracic diameter on x-ray, or extramediastinal mass >6 cm), 3B, 4 Age 2-21y	5 cycles of BV-AVEPC vs. standard ABVEPC Not interim PET-adapted	3.5y	**All:** 3y EFS 92.1% with BV-AVEPC vs. 82.5% with ABVEPC (p<0.001)	**All:** 3y OS 99.3% with BV-AVEPC vs. 98.5% with ABVEPC	BV-AVEPC CDA endorsed in 2024 in ages 2–21y, 2B bulky, 3B, 4. Greatest benefit in 2B bulky (HR: 0.09).
SWOG S1826[25] n=994	Stage 3–4 Age ≥12y	6 cycles of N-AVD vs. BV-AVD Not interim PET-adapted	2.1y	**All:** 2y PFS 92% with N-AVD vs. 83% with BV-AVD (HR: 0.45, 95% CI: 0.30–0.65)	**All:** 2y OS 99% with N-AVD vs. 98% with BV-AVD (HR: 0.39, 95% CI: 0.15–1.03)	N-AVD a new standard in stage 3–4. Striking results in older adults ≥60y. Extrapolated to early unfavourable disease (with RT) in NCCN guidelines. CDA endorsed June 2025, funding approved.

Table 2. Select clinical trials in advanced stage cHL leading to practice changes in Canada; *courtesy of Jowon L. Kim, MD and Kerry J. Savage, MD.*

#: Either 6 cycles BEACOPP14 (if PET-negative after 4 cycles) or 4 cycles of escBEACOPP (if PET-negative after 3 cycles). Salvage if interim PET-positive after switching to BEACOPP.

Abbreviations: ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; **ABVEPC:** doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide; **BrECADD:** brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone; **BV-AVD:** brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine; **BV-AVEPC:** brentuximab vedotin, doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide; **CDA:** Canada's Drug Agency; **CI:** confidence interval; **D:** Deauville; **EOT:** end of treatment; **escBEACOPP:** bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; **HR:** hazard ratio; **N-AVD:** nivolumab, doxorubicin, vinblastine, and dacarbazine; **NCCN:** National Comprehensive Cancer Network; **Neg:** negative; **OS:** overall survival; **PET:** positron emission therapy; **PET2:** interim PET scan after 2 cycles; **PFS:** progression-free survival; **Pos:** positive; **Pts:** patients; **R:** rituximab; **RT:** radiation therapy; **Y:** years.

Trial	Longest median follow-up	Peripheral neuropathy	Febrile neutropenia	Grade ≥3 toxicity	Treatment-related mortality	Treatment discontinuation due to toxicity	Secondary malignancy	Pregnancy/fertility outcomes
RATHL[1,22]	7.3y	Not reported	5% in ABVD, 2% in AVD, 17% in BEACOPP (G-CSF mandated)	69% with ABVD, 65% with AVD, 81% with BEACOPP	0.9% in ABVD, 0% in AVD, 2% in escBEACOPP	Not reported	**Secondary malignancies at 7y:** 5.1% in ABVD, 5.8% in AVD, 2.5% in escBEACOPP **Secondary AML/MDS:** not observed	Not reported
GITIL/FIL HD0607[11,14]	5.9y	Not reported	Not reported	**Hematologic:** 76% with BEACOPP vs. 30% with ABVD **Infections:** 10% with BEACOPP vs. 1% with ABVD **Pulmonary toxicity:** 1% with BEACOPP vs. 2% with ABVD	<1%	Not reported	**Secondary malignancies:** none with 3.6y follow-up, 2% in 5.9y follow up of pts with LNM (all received RT) **Secondary AML/MDS:** not observed	Not reported
AHL 2011[17,23]	5.6y	23% in standard arm vs. 22% in PET-adapted arm	35% in standard arm vs. 23% in PET-adapted arm (G-CSF mandated with escBEACOPP)	**Neutropenia:** 87% with standard arm vs. 90% with PET-adapted arm **Anemia:** 69% with standard arm vs. 28% with PET-adapted arm **Thrombocytopenia:** 66% with standard arm vs. 40% with PET-adapted arm **Infections:** 22% with standard arm vs. 11% with PET-adapted arm	1% in standard arm vs. <1% in PET-adapted arm	7% in standard arm vs. <1% in PET-adapted arm	**Second malignancies:** 3.2% in standard arm, 2.2% in PET-adapted arm **Secondary AML:** 1% in standard arm, 0.5% in PET-adapted arm	**Pregnancies:** 8.5% in 6escBEACOPP, 12.5% in 2escBEACOPP + 4ABVD **Assisted reproductive technology use:** 20.5% in 6escBEACOPP vs. 10.8% in 2escBEACOPP + 4ABVD
ECHELON-1[7,24]	6.1y	29% with BV-AVD vs. 17% with ABVD	**Serious AE of febrile neutropenia, sepsis, or infections:** 24% with BV-AVD (G-CSF mandated) vs. 9% with ABVD	83% with BV-AVD vs. 66% with ABVD	1% in both arms	13% with BV-AVD vs. 16% with ABVD	**Secondary cancer:** 3.5% with BV-AVD vs. 4.9% with ABVD **Secondary AML/MDS:** 2 in each arm	**Pregnancies:** 114/82 couples with BV-AVD and 81/61 couples with ABVD
GHSG HD21[26]	4y	43% with BrECADD vs. 53% with escBEACOPP	28% with BrECADD vs. 21% with escBEACOPP	**Febrile neutropenia:** 28% with BrECADD vs. 21% with escBEACOPP **Infections:** 20% with BrECADD vs. 19% with escBEACOPP **Organ toxicity grade ≥3:** 19% with BrECADD vs. 17% with escBEACOPP **Grade 4 hematologic AE or infection:** 31% with BrECADD vs. 52% with escBEACOPP	**Treatment-related mortality:** <1% with both arms **Treatment-related morbidity:** 42% with BrECADD vs. 59% with escBEACOPP; p<0.0001	2% with BV vs. 18% with vincristine	**Secondary cancer:** 3% with BrECADD vs. 2% with escBEACOPP **Secondary AML/MDS:** <1% with BrECADD, 1% with escBEACOPP	**Gonadal function recovery (FSH level):** 95% with BrECADD vs. 72.5% with escBEACOPP in women; 86% with BrECADD vs. 39% with escBEACOPP in men **Successful childbirths:** 62/59 with BrECADD, 46/40 with escBEACOPP

Trial	Longest median follow-up	Peripheral neuropathy	Febrile neutropenia	Grade ≥3 toxicity	Treatment-related mortality	Treatment discontinuation due to toxicity	Secondary malignancy	Pregnancy/fertility outcomes
AHOD1331[2]	3.5y	**Grade ≥2:** 19% in both arms	31% with with BV-AVEPC vs. 33% with ABVEPC	74% with BV-AVEPC vs. 68% with ABVEPC	None	Not reported **Dose modifications:** 13% with BV-AVEPC vs. 23% with ABVEPC	**Secondary cancers:** 1 in both arms (<1%) **Secondary AML:** 1 in BV-AVEPC arm	Not reported
SWOG S1826[25]	2.1y	29% with N-AVD vs. 56% with BV-AVD	**Febrile neutropenia:** 6% with N-AVD vs. 7% BV-AVD (GCSF mandated) **Neutropenia:** 56% with N-AVD vs. 34% BV-AVD **G-CSF use:** 56% with N-AVD (not mandated) vs. 97% with BV-AVD (mandated) **Sepsis:** 2% with N-AVD vs. 3% BV-AVD	**Febrile neutropenia:** 6% with N-AVD vs. 7% with BV-AVD **Infections:** 2% with N-AVD vs. 3% with BV-AVD **Neuropathy:** 1% with N-AVD vs. 8% with BV-AVD **LFT elevation:** 7% with N-AVD vs. 8% with BV-AVD **Possible immune-related AE (all grades):** **Thyroid abnormalities:** 10% with N-AVD vs. <1% with BV-AVD **Rash:** 15% in both arms LFT elevation: 38% with N-AVD vs. 76% with BV-AVD	<1% with N-AVD vs. 1% with BV-AVD	9% with nivolumab vs. 22% with BV	Not reported	Not reported

Table 3. Safety outcomes in advanced stage cHL trials; *courtesy of Jowon L. Kim, MD and Kerry J. Savage, MD.*

Abbreviations: ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; **AE:** adverse event; **ABVEPC:** doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide; **AML:** acute myeloid leukemia; **BrECADD:** brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone; **BV:** brentuximab vedotin; **BV-AVD:** brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine; **BV-AVEPC:** brentuximab vedotin, doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide; **escBEACOPP:** bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; **G-CSF:** granulocyte colony-stimulating factor; **LFT:** liver enzyme; **LNM:** large nodal mass; **MDS:** myelodysplastic syndrome; **N-AVD:** nivolumab, doxorubicin, vinblastine, and dacarbazine; **Neg:** negative; **OS:** overall survival; **PET:** positron emission therapy; **PFS:** progression-free survival; **Pos:** positive; **RT:** radiation therapy; **Y:** years.

standard ABVEPC.[2] Consolidative involved site RT was administered to those with a large mediastinal mass at diagnosis, PET2-positive "slow-responding lesions" (D4-5), and EOT PET-positive (D3-5) lesions, resulting in 53% and 57% receiving RT in the BV and standard arms, respectively. An improved event-free survival (EFS), an endpoint that includes the development of secondary neoplasm, was observed with a 3-year EFS of 92.1% vs. 82.5% (HR: 0.41, 95% CI: 0.25–0.67) in favour of the BV arm, with greater benefit seen in stage 2B bulky disease (HR: 0.09, 95% CI: 0.01–0.69).

Nivolumab (N)-AVD

Reed-Sternberg cells frequently overexpress programmed cell death ligand 1 (PD-L1) and 2 (PD-L2), contributing to immune evasion and making them particularly susceptible to programmed cell death protein 1 (PD-1) blockade. Anti-PD-1 antibodies demonstrated striking efficacy in the relapsed/refractory setting (ORR 64–74%, CR: 12–29%), leading to approval of both pembrolizumab and nivolumab, including in Canada.[27,28,30] The Phase 3 KEYNOTE-204 study confirmed improved PFS (median 13.2 vs 8.3 months, p=0.003) of pembrolizumab over BV in relapsed/refractory cHL (including "transplant ineligible", a definition that includes insufficient response to salvage therapy for those planned for autologous stem cell transplant).[30]

The landmark SWOG S1826 trial compared nivolumab-AVD (N-AVD) to BV-AVD in patients aged ≥12 years with stage 3–4 cHL.[25] At a median follow-up of 2.1 years, N-AVD demonstrated superior PFS compared to BV-AVD (2-year PFS: 92% vs. 83%; HR: 0.45, 95% CI: 0.30-0.65) and similar OS (99% vs. 98%). Importantly, N-AVD showed remarkable efficacy in patients >60 years, with superior 2-year PFS (89% vs. 64%, p=0.001) and OS (96% vs. 85%, p=0.005).[31] N-AVD was better tolerated, and although there was more grade ≥3 neutropenia (48% vs. 26%), febrile neutropenia rates were similar, even though granulocyte colony-stimulating factor (G-CSF) was not mandated in the N-AVD arm (although we would endorse use in this age group regardless).[25] Overall, immune-related adverse events (irAE) were low, with expected hypo/hyperthyroidism more frequent in the N-AVD arm. Consolidative RT to residual metabolically active lesions was allowed if the intent was pre-specified, but not mandated. Excellent outcomes were observed with near elimination of consolidative RT use (0.7% regardless of arm). Minimizing RT use is of particular significance in AYA patients, in whom future secondary cancers and cardiac disease remain a concern. N-AVD is now listed in the NCCN guidelines for stage 3–4 disease. The NCCN guidelines also include both N-AVD (adapted from the Phase 2 study NIVAHL[32]) and BV-AVD (adapted from the Phase 2 study BREACH[33]) for 4 cycles in combination with RT, as treatment options in stage 1/2 unfavourable cHL.[33] Longer follow-up is needed to confirm response durability, long-term side effects, and impact on fertility. N-AVD recently received a positive CDA endorsement in Canada (June 2025) for use in patients ≥12 years of age with stage 3–4 cHL. As of this writing, the CDA endorsed inclusion of high-risk stage 2 patients along with stage 3 and 4 indication and has been funding approved by the pan-Canadian Pharmaceutical Alliance (pCPA) with provinces rolling out their programs over the next few months.

Older Patients with cHL

Older patients with advanced stage cHL have shown inferior outcomes with conventional therapies, due to higher toxicity and more treatment-resistant tumour biology.[35] In a subgroup of older patients (≥60 years) from the ECHELON-1 trial, although not powered for this comparison, there was no improvement in PFS with BV-AVD (5-year PFS 67.1% with BV-AVD vs. 61.6% with ABVD, p=0.44), and it was associated with increased grade ≥3 neuropathy (18% vs 3%), febrile neutropenia (37% vs. 17%), and more dose modifications (80% vs. 71%).[36] Studies have suggested that HL patients ≥70 years have particularly worse outcomes.[35] A Phase 2 study of sequential administration of BV and AVD (i.e., BV x 4, AVD x 6, BV x 2) in patients >60 years demonstrated improved outcomes (2-year PFS: 84%, OS: 93%) and tolerance compared to historical expectations; however, treatment duration is long and neuropathy still a concern.[35,37,38] Preliminary results from a Phase 2 study assessing BrECADD in patients aged 61–75 years with a median follow-up of almost 2 years demonstrated very encouraging results (2-year PFS: 91.5%) and no treatment-related deaths, although febrile neutropenia occurred in 54% of patients.[39] However, this regimen is unlikely to supplant N-AVD given the excellent tolerance and OS advantage over BV-AVD demonstrated in older patients observed in the SWOG1826 study.[31] Treatment

was much better tolerated in the N-AVD arm, with less discontinuation (14% vs. 55%), febrile neutropenia (12% vs. 19%; despite mandated G-CSF with BV-AVD), infections (18% vs. 34%), and neuropathy (33% vs. 68%), also allowing delivery in those aged >80 years.[31,40] With even longer follow-up, similar results were observed in a separate phase 2 study of N-AVD in this age group (3-year PFS 79%, OS 97%).[41]

Canadian Landscape

N-AVD now has CDA endorsement and funding negotiations are complete. Some provinces can already access this regimen for advanced stage patients and fortunately, high-risk stage 2 patients were also included. A recent study from BC Cancer suggests this is highly relevant in the AYA group, as these patients frequently present with high-risk stage 2 disease, and when treated with ABVD, have outcomes similar to stage 3 and 4, and more frequent RT use due to incomplete response.[42] BrECADD is still under CDA review but given the level of evidence, it will also be an available regimen for patients. One remaining question is whether there is a very low-risk group with excellent outcomes with ABVD alone (RATHL approach) given the potential for chronic irAE with PD1 inhibitors observed in melanoma.[43]

New challenges will include personalizing therapy choice, managing novel toxicities, sequencing of therapies in patients with relapsed disease post novel front-line therapies, and ensuring equitable access. As PD-1 inhibitors have been shown to synergize with other therapies, there can be re-induction of response at relapse.[44] BV-based regimens may also be appealing in this setting. In Canada, GDP is the only approved combination in the transplant-eligible population with an ongoing Canadian Cancer Trials Group (CCTG) randomized Phase 2 study comparing GDP to BV-pembrolizumab (NCT05180097). Refinement of conventional PET-based interim response assessment with circulating tumour DNA assessment may aid in selecting patients who may benefit from a more intensive approach or who can have shorter therapy duration.[45] Canadian oncologists and policymakers face complex yet exciting decisions to further refine treatment in advanced stage cHL.

Correspondence

Kerry J. Savage, MD
Email : ksavage@bccancer.bc.ca

Financial Disclosures

J.L.K.: None declared.
K.J.S.: None declared.

References

1. Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, et al. adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374(25):2419–29.
2. Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, et al. Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin's lymphoma. N Engl J Med. 2022;387(18):1649–60.
3. Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi trial. J Clin Oncol. 2009;27(5):805–11.
4. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–12.
5. Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016;34(11):1175–81.
6. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, et al. Randomized Phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013;31(6):684–91.
7. Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, et al. Overall survival with brentuximab vedotin in Stage III or IV Hodgkin's lymphoma. N Engl J Med. 2022;387(4):310–20.
8. Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99(6):1107–13.
9. Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54(5):683–90.

10. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]Fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746–52.
11. Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mulé A, et al. early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 Trial. J Clin Oncol. 2018;36(5):454–62.
12. Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019;134(15):1238–46.
13. Ricardi U, Levis M, Evangelista A, Gioia DM, Sacchetti GM, Gotti M, et al. Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. Blood Adv. 2021;5(21):4504–14.
14. Gallamini A, Rossi A, Patti C, Picardi M, Romano A, Cantonetti M, et al. Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL/FIL HD0607 trial. J Clin Oncol. 2020;38(33):3905–13.
15. LaCasce AS, Dockter T, Ruppert AS, Kostakoglu L, Schöder H, Hsi E, et al. positron emission tomography–adapted therapy in bulky stage I/II classic Hodgkinlymphoma: CALGB 50801 (Alliance). J Clin Oncol. 2022;41(5):1023-34.
16. Kim JL, Villa D, Tonseth RP, Gerrie AS, Wilson D, Benard F, et al. Long-term follow-up of bulky classic Hodgkin lymphoma managed with ABVD and PET-guided RT demonstrates excellent outcomes in PET-negative cases. Br J Haematol. 2025;206(1):167–71.
17. Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20(2):202–15.
18. Straus DJ, Długosz-Danecka M, Connors JM, Alekseev S, Illés Á, Picardi M, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021;8(6):e410–21.
19. Zheng S, Gupta K, Goyal P, Nakajima R, Michaud L, Batlevi CL, et al. outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting. Cancers. 2023;15(6):1760.
20. Hamid MS, Rutherford SC, Jang H, Kim S, Patel K, Bartlett NL, et al. outcomes among classical Hodgkin lymphoma patients after an interim PET scan: a real-world experience. Clin Lymphoma Myeloma Leuk. 2022;22(7):e435–42.
21. Kim JL, Villa D, Tonseth RP, Gerrie AS, Wilson D, Benard F, et al. Evaluation of long-term outcomes in advanced stage classic Hodgkin lymphoma treated with ABVD using a PET-guided strategy. HemaSphere. 2025;9(S1):1135–6.
22. Luminari S, Fossa A, Trotman J, Molin D, d'Amore F, Enblad G, et al. long-term follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma trial. J Clin Oncol. 2024;42(1):13–8.
23. Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, et al. Positron emission tomography–driven strategy in advanced Hodgkin lymphoma: prolonged follow-up of the AHL2011 Phase III Lymphoma Study Associationstudy. J Clin Oncol. 2022;40(10):1091–101.
24. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018;378(4):331–44.
25. Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, et al. Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma. N Engl J Med. 2024;391(15):1379–89.
26. Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet. 2024;404(10450):341–52.
27. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–32.
28. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed/refractory classic Hodgkin Lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm Phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428–39.
29. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183–9.
30. Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021;22(4):512–24.
31. Rutherford SC, Li H, Herrera AF, LeBlanc M, Ahmed S, Davison K, et al. Nivolumab-AVD Versus brentuximab vedotin–AVD in older patients with advanced-stage classic Hodgkin lymphoma enrolled on S1826. J Clin Oncol. 2025;0(0):JCO-25-00204.

32. Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, et al. Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group Phase II NIVAHL trial. J Clin Oncol. 2023;41(6):1193–9.
33. Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial. J Clin Oncol. 2023;41(2):327–35.
34. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hodgkin lymphoma. [Internet]. National Comprehensive Cancer Network; 2025 [cited 2025 Jun 19]. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439
35. Cheng PTM, Villa D, Gerrie AS, Freeman CL, Slack GW, Gascoyne RD, et al. The outcome of older adults with classic Hodgkin lymphoma in British Columbia. Blood Adv. 2022;6(22):5924–32.
36. Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, et al. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. 2021;107(5):1086–94.
37. Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, et al. The efficacy and tolerability of ABVD and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American Intergroup Trial E2496. Br J Haematol. 2013;161(1):76–86.
38. Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, et al. Multicenter phase II Study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol. 2018;36(30):3015–22.
39. Ferdinandus J, Kaul H, Fosså A, Hüttmann A, Keil F, Ko YD, et al. PET-guided brecadd in older patients with advanced-stage classic Hodgkin lymphoma: results of the phase 2 part of the GHSG HD21 trial. Blood. 2024;144(Supplement 1):568.
40. Rutherford SC, Li H, Herrera AF, Leblanc M, Ahmed S, Davison KL, et al. Nivolumab-AVD Is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged ≥60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826. Blood. 2023;142:181.
41. Torka P, Feldman T, Savage KJ, Ganesan N, Drill E, Hancock H, et al. Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma. J Clin Oncol. 2025 Mar 10;43(8):985–93.
42. Kim JL, Villa D, Gerrie AS, Tonseth RP, Wilson D, Benard F, et al. Adolescent/ young adult (aya) patients with high-risk stage 2 classic Hodgkin lymphoma have similar outcomes to stage 3 or 4 with 6 cycles of ABVD chemotherapy. Hematol Oncol. 2025;43(S3):e128_70093.
43. Patrinely JR Jr, Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, et al. Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol. 2021 May 1;7(5):744–8.
44. Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023 Sep 7;142(10):878–86.
45. Paczkowska J, Kaszkowiak M, LeBlanc M, Stewart C, Herrera AF, Fernando del Castillo JC, et al. Prognostic value of circulating tumor DNA in patients with advanced stage classic Hodgkin lymphoma treated on Swog S1826. Hematol Oncol. 2025;43(S3):e21_70093.

GET TO KNOW THE YESCARTA® CAR T STORY

CHAPTER 2

TRUST THE EXPERIENCE AND RELIABLE DELIVERY OF YESCARTA CAR T THERAPY

#1 **YESCARTA IS THE #1 DELIVERED CAR T THERAPY IN CANADA**[1†]

Delivery you can count on:[2,3‡]

- 100% preferred apheresis slots selection
- 98% manufacturing success rate
- 14-day median turnaround time[§]

Trust in the experience of YESCARTA

Over 24,000 patients have been treated with YESCARTA worldwide.[4‡]

CONTINUE THE YESCARTA CAR T STORY
Scan the code for information on authorized Kite CAR T treatment centres

Pr YESCARTA® (axicabtagene ciloleucel) Suspension for IV infusion

quis aliquet ... ue eleifend ... Donec arcu ... gue, felis a ... justo arcu, ... e convallis ... Sed luctus ... ere. Ut nec ... unt ipsum ... que tortor ... etra quis, ... uam nisi ... n, sagittis ... justo ut ... nt. Nulla ... sectetur ... et ligula ... s massa ... m quis, ... ringilla, ... lacinia ... lapibus ... tis nibh ... itae mi ... em, sit ... iverra. ... unc, in ... ectus ... Nunc ... suada ... disse ... tetur ... usto ... assa ... mus ... etur ... que ... vel. ... ous ... vel ... lis. ... sis ... ed ... ent ... or ... s, ... si ... s ... t ... a ... r

... cleifend ut. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla eget justo vitae mi cursus scelerisque sed nec sapien.

Vivamus laoreet consequat tellus, id porta ipsum semper et. Morbi eu rhoncus lorem, sit amet molestie sem. Morbi iaculis consectetur euismod. Sed tristique vehicula viverra. Donec tincidunt imperdiet mattis. Phasellus quis eros enim. Morbi mattis dignissim nunc, in sollicitudin dolor maximus vitae. Pellentesque viverra, lacus ac semper pulvinar, massa lectus ultricies dolor, suscipit luctus ex augue id risus. Fusce condimentum facilisis vulputate. Nunc quis vehicula augue.

CAR T=chimeric antigen receptor T cell therapy.
† Comparative clinical significance is unknown.
‡ Clinical significance has not been established.
§ Turnaround time refers to time from leukapheresis to product ready.

References: 1. Data on File. IQVIA. **2.** Data on File. YESCARTA Manufacturing Analytics (Kite Konnect). May 2025. Gilead Sciences Canada, Inc. **3.** Data on File. Turnaround time for YESCARTA. February 2025. Gilead Sciences Canada, Inc. **4.** Data on File. Number of patients treated. May 2025. Gilead Sciences Canada, Inc. **5.** YESCARTA Product Monograph. Gilead Sciences Canada, Inc.

YESCARTA (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with:

- diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy;
- relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), HGBL, and DLBCL arising from follicular lymphoma;

YESCARTA, indicated for:

- the treatment of adult patients with relapsed or refractory grade 1, 2 or 3a follicular lymphoma (FL) after two or more lines of systemic therapy

has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization.

Most Serious Warnings and Precautions:

Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving YESCARTA. Delay YESCARTA treatment if a patient has active uncontrolled infection or inflammatory disorders, active graft-versus-host disease (GVHD) or unresolved serious adverse reactions from prior therapies. Monitor for CRS after treatment with YESCARTA. Provide supportive care, tocilizumab, or tocilizumab and corticosteroids, as needed.

Neurologic adverse reactions, including fatal or life-threatening reactions, occurred in patients receiving YESCARTA, including concurrently with CRS or independently of CRS. Monitor for neurologic adverse reactions after treatment with YESCARTA. Provide supportive care, tocilizumab (if with concurrent CRS), or corticosteroids, as needed.

Administration: YESCARTA should be administered by experienced health professionals at specialized treatment centres.

Other Relevant Warnings and Precautions:

- YESCARTA should be administered at a specialized healthcare/clinical facility with personnel trained in handling and administering YESCARTA and in the management of patients treated with YESCARTA, including monitoring and managing CRS and neurotoxicity. The facility should have immediate access to appropriate emergency equipment and intensive care unit.
- For autologous use only. Under no circumstances should it be administered to other patients.
- Before infusion, the patient's identity must match the patient identifiers on the YESCARTA cassette.
- Safety and efficacy have not been established in patients with central nervous system (CNS) lymphoma.
- Patients should not donate blood, organs, tissues and cells for transplantation.
- Patients should receive life-long monitoring for secondary malignancies.
- Driving, operating machinery, and other hazardous occupations or activities should be avoided in the 8 weeks following YESCARTA infusion.
- Risk of tumour lysis syndrome (TLS).
- Risk of B-cell aplasia and hypogammaglobulinemia.
- Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during YESCARTA treatment, and until immune recovery following treatment with YESCARTA.
- Allergic reactions may occur with YESCARTA infusion. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO) or residual gentamicin in YESCARTA.
- Risk of prolonged cytopenias.
- Risk of severe or life-threatening infections. Should not be administered to patients with clinically significant active infections.
- Risk of febrile neutropenia.
- Risk of life-threatening and fatal opportunistic infections including disseminated fungal infections and viral reactivation in immunosuppressed patients.
- Risk of reactivation of hepatitis B virus (HBV), human polyomavirus 2 (JC virus; the cause of progressive multifocal leukoencephalopathy [PML]) and human herpesvirus 6 (HHV-6).
- Patients must be monitored at least daily for 7 days at the specialized healthcare/clinical facility following infusion for signs and symptoms of CRS and neurologic adverse reactions.
- CRS and neurologic adverse reactions can occur more than 7 days after the infusion. Instruct patients to remain within proximity of the specialized healthcare/clinical facility for at least 4 weeks following infusion.
- Educate patients and their caregivers for signs and symptoms of CRS and neurologic adverse reactions.
- Advise patients and their caregivers to immediately contact the designated health professional if CRS or neurologic adverse reactions are suspected.
- YESCARTA is not recommended for women who are pregnant, and pregnancy after YESCARTA infusion should be discussed with the treating physician. Sexually active females of reproductive potential should have a pregnancy test prior to starting treatment and should use effective contraception (methods that result in less than 1% pregnancy rates) after YESCARTA administration. Sexually active males who have received YESCARTA should use a condom during intercourse with females of reproductive potential or pregnant women. See the Product Monographs for fludarabine and cyclophosphamide for information on the need for effective contraception in patients who receive the lymphodepleting chemotherapy. There are insufficient data to provide a recommendation concerning duration of contraception following treatment with YESCARTA.
- Precaution should be exercised for breastfeeding.
- No data in patients <18 years old are available to Health Canada: therefore, Health Canada has not authorized an indication for pediatric use.
- No dose adjustment required in patients ≥65 years of age.

For More Information:

- Please consult the Product Monograph at www.gilead.ca/pdf/ca/YESCARTA_pm_english.pdf for important information relating to adverse reactions, interactions, and dosing which has not been discussed in this piece. The Product Monograph is also available by calling Gilead Sciences Canada, Inc. at 1-866-207-4267.

GILEAD | Kite

Pr YESCARTA® (axicabtagene ciloleucel) Suspension for IV infusion

doi.org/10.58931/cht.2025.4378

About the Author

Christopher Lemieux, MD, FRCPC, DRCPC

Dr. Christopher Lemieux is a Hematologist at the CHU de Québec-Université Laval. He completed specialized training in transplantation and cell therapy at Stanford University in California, for which he received the Detweiler scholarship from the Royal College of Physicians and Surgeons of Canada and the Stephen Couban prize of the Canadian Hematology Society. He is currently director of the CAR-T program at the CHU de Québec-Université Laval and is a member of the immunocellular therapy network in Québec. He is a Clinical Associate Professor of Medicine and director of the Hematology fellowship program at Université Laval.

Affiliations: CHU de Québec – Université Laval, Québec, Québec.

Practical Management of Aggressive B-Cell Lymphomas with CD20×CD3 Bispecific Antibodies

Christopher Lemieux, MD, FRCPC, DRCPC

CD20×CD3 bispecific antibodies (BsAbs) have transformed the therapeutic landscape of relapsed or refractory large B-cell lymphoma (LBCL). By redirecting T cells to target CD20-expressing lymphoma cells, these off-the-shelf agents offer high response rates and durable remissions in patients who previously had limited options, including those who relapse after chimeric antigen receptor T-cell therapy. In Canada, epcoritamab and glofitamab are now approved for patients with LBCL after at least two prior lines of treatment. The combination of glofitamab, gemcitabine, and oxaliplatin has been recently approved for patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified LBCL after at least 1 line of therapy and who are ineligible for autologous hematopoietic stem cell transplant. This review provides a practical framework for Canadian hematologists: identifying eligible patients, implementing pretreatment evaluation, safely delivering therapy in inpatient and outpatient settings, and managing toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. We will also discuss infection prophylaxis, sequencing with cellular therapies, and future directions for BsAbs in earlier treatment lines.

Introduction

Despite advances with immunochemotherapy, autologous hematopoietic stem cell transplantation, and chimeric antigen receptor (CAR) T-cell therapy, relapsed or refractory (R/R) large B-cell lymphoma (LBCL) remains incurable in more than half of patients.[1-6] Also, approximately 30–40% of patients are not candidates for CAR T-cell therapy because of comorbidities or logistical barriers.[7,8] For these patients, outcomes have historically been poor, with median overall survival measured in months.[9] Unlike CAR T-cell therapy, bispecific antibodies (BsAbs), such as the CD20xCD3 BsAbs glofitamab and epcoritamab, are readily available, can be administered without manufacturing delays, and are feasible in both academic and community settings.[10-12]

Indications and Patient Selection

In Canada, glofitamab is approved for the treatment of adult patients with R/R diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL transformed from indolent follicular lymphoma (FL), or primary mediastinal B-cell lymphoma after two or more lines of systemic therapy, for those who have previously received or are unable to receive CAR T-cell therapy.[13] Epcoritamab is approved for the same indications, as well as for high-grade lymphoma, DLBCL transformed from indolent lymphoma, and grade 3B FL.[14]

Both epcoritamab and glofitamab demonstrated high response rates and durable remissions in heavily pretreated populations. In the EPCORE NHL-1 study, epcoritamab achieved an overall response rate (ORR) of 63% with 39% complete responses (CR) in patients who had a median of three prior therapies (range 2–11), including CAR T-cell therapy (38,9%).[15] Responses were durable at two years of follow-up in a significant proportion of responders. Among patients who achieved a CR, 64% remained in CR at 2 years.[16] Similarly, glofitamab showed an ORR of 52% and a CR rate of 39% in its pivotal trial, which included patients previously treated with CAR T-cell therapy (33.1% of patients in the trial), with long-term remissions documented even in those with post–CAR T-cell therapy relapse.[8,17] The populations most likely to benefit from these treatments are those ineligible for CAR T-cell therapy due to comorbidities or age, those relapsing after CAR T-cell therapy, and patients with rapidly progressive disease requiring immediate therapy.[8,18] However, responses are less favourable when relapse occurs within three months of CAR T-cell therapy.[7] In Canadian practice, where CAR T-cell therapy access may be limited for patients living far from an approved CAR T centre, BsAbs provide an important and scalable alternative.

More recently, the combination of glofitamab, gemcitabine, and oxaliplatin (Glofit-GemOx) was approved for patients with R/R DLBCL NOS, after at least 1 line of therapy, who are ineligible for autologous hematopoietic stem cell transplant.[13] This approval represents a major advance for patients who historically had limited therapeutic options when a transplant was not feasible.[19] The STARGLO Phase III trial compared Glofit-GemOx with the standard rituximab, gemcitabine, and oxaliplatin (R-GemOx) regimen in transplant-ineligible patients. Glofit-GemOx demonstrated a clear and clinically meaningful improvement in outcomes. The median overall survival was not reached with Glofit-GemOx versus 13.5 months with R-GemOx, translating into a 24-month overall survival rate of 54.4% versus 33.6%, respectively. Similarly, the median progression-free survival was 13.8 months for Glofit-GemOx and 3.6 months for R-GemOx. Response rates were also superior, with a CR rate of 58% in the Glofit-GemOx arm versus 25% in the R-GemOx arm.[20] These findings establish Glofit-GemOx as a new standard of care for patients with R/R DLBCL who are not candidates for autologous hematologic stem cell transplantation, bridging an important therapeutic gap, and further highlighting the potential of BsAb-based combinations in aggressive B-cell lymphomas.

Pretreatment Evaluation

Safe delivery of BsAbs requires a thorough pretreatment assessment. Histologic confirmation of CD20-positive LBCL is recommended. Loss of CD20 is reported in up to 12 % of patients.[21] Repeating a biopsy prior to BsABs might be useful even after documentation of the loss of CD20, as one report has shown the reoccurrence of the expression of CD20.[22] Laboratory work should include complete blood count, renal and hepatic function, lactate dehydrogenase, and baseline immunoglobulins.[10] All patients require Hepatitis B virus (HBV) serologies (HBsAg, anti-HBc,

anti-HBs). HBsAg-positive or anti-HBc–positive patients should begin antiviral prophylaxis before the first BsAb dose.[23] Screening for Hepatitis C (HCV) and human immunodeficiency virus (HIV) is recommended, and vaccination history should be reviewed. Prophylaxis against *Pneumocystis jirovecii* and herpesviruses is recommended. Intravenous immunoglobulin (IVIG) may be needed to prevent recurrent infections or treat hypogammaglobulinemia. Institutional readiness is crucial; tocilizumab must be stocked, staff should be trained in toxicity recognition and cytokine release syndrome (CRS) and immune effector cell-associated toxicity syndrome (ICANS) management protocol should be considered.[10]

Administration and Toxicity Management

Treatment with both glofitamab and epcoritamab uses step-up dosing to reduce the risk of cytokine release syndrome (CRS). Epcoritamab is administered subcutaneously, with weekly doses during the initial cycles, after which it is administered less frequently.[14] Glofitamab is given intravenously following a pre-dose of obinutuzumab, with treatment limited to 12 cycles.[13] The first higher step-up dose is often administered in a hospital or under extended observation, especially in patients with bulky disease or comorbidities.[13] Emerging evidence, including from the EPCORE NHL-6 study, supports outpatient administration in selected patients with structured monitoring pathways.[24] Premedication with dexamethasone has significantly reduced the incidence of CRS and should now be considered the standard of care for BsAbs CRS prophylaxis.[25]

CRS is the most common adverse event, affecting 30–60% of patients, usually in cycles 1–2.[15,18,20] Most CRS events are grades 1 or 2. Management follows the American Society for Transplantation and Cellular Therapy (ASTCT) consensus: supportive care for grade 1, tocilizumab for grade ≥2, and corticosteroids for persistent cases.[26] Immune effector cell-associated neurotoxicity syndrome (ICANS) is less frequently observed but clinically important. Symptoms include confusion, aphasia, or seizures. Corticosteroids are the mainstay of management.[10,26] Cytopenias and infections are also common, and may require granulocyte colony-stimulating factor (G-CSF) support, antimicrobial prophylaxis, and sometimes IVIG.[10] Standardized toxicity algorithms have been published and adapted by Canadian centres.[12] Outpatient administration is increasingly used to address resource limitations, with structured protocols ensuring safety through careful patient selection, standardized premedication, and early toxicity monitoring. With dedicated infusion pathways, rapid access to acute care, and robust patient education, many centres now manage most patients entirely as outpatients, preserving inpatient capacity while maintaining safety.[12]

Sequencing with CAR-T and Transplant

BsAbs demonstrate activity after CAR T-cell relapse, though outcomes are worse after an early relapse.[7,15,18] Importantly, prior BsAb exposure does not appear to compromise later CAR T-cell therapy efficacy.[27] For younger patients who achieve remission with a BsAb, allogeneic hematopoietic stem cell transplantation may be considered as consolidation in select cases.[28]

Conclusion

BsAbs represent an effective therapeutic option in R/R LBCL. Combined with GemOx, glofitamab now constitutes a new standard of care for patients ineligible for autologous hematopoietic stem cell transplant. With careful patient selection, structured monitoring, and standard toxicity management, these therapies can be delivered safely across Canada. They also complement CAR T-cell therapy therapy and are likely to play an increasing role in front-line therapy.

Correspondence

Christopher Lemieux, MD, FRCPC, DRCPC
Email : christopher.lemieux.med@ssss.gouv.qc.ca

Financial Disclosures

C.L.: Advisory board: AbbVie, BMS, Kite-Gilead, Incyte and Roche.

References

1. Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675-84.
2. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2021.

3. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540-5.
4. Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307-15.
5. Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024;143(5):404-16.
6. Alarcon Tomas A, Fein JA, Fried S, Flynn JR, Devlin SM, Fingrut WB, et al. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma. Leukemia. 2023;37(1):154-63.
7. Shumilov E, Scholz JK, Seib M, Mazzeo P, Wurm-Kuczera R, Vucinic V, et al. Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma. Blood Adv. 2025;9(15):3955-66.
8. Cartron G, Houot R, Al Tabaa Y, Le Bras F, Ysebaert L, Choquet S, et al. Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study. Nat Cancer. 2025.
9. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8.
10. Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, et al. Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood. 2024;143(16):1565-75.
11. Fleury I, MacDonald D, Shafey M, Christofides A, Sehn LH. Optimal use of bispecific antibodies for the treatment of diffuse large B-cell lymphoma in Canada. Curr Oncol. 2025;32(3).
12. MacDonald D, Puckrin R, Skrabek P, Lam S, Jayakar J, Fleury I, et al. Practical Guidance for the expanded implementation and provision of bispecific antibodies for diffuse large B-cell lymphoma (DLBCL) across Canada. Curr Oncol. 2025;32(8).
13. Columvi Glofitamab injection Product Monograph. Hoffmann-La Roche Limited. Mississauga, ON; September 16, 2025.
14. Epkinly epcoritamab injection Product Monograph. AbbVie Corporation. St-Laurent, Quebec; April 2024.
15. Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a Phase I/II trial. J Clin Oncol. 2023;41(12):2238-47.
16. Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024;38(12):2653-62.
17. Brooks TR, Zabor EC, Bedelu Y, Yang X, Karimi YH, Nefved AN, et al; Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. Published online July 15, 2025.
18. Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220-31.
19. Ayers EC, Margolis D, Landsburg DJ. Real world outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma receiving palliative intent therapies. Clin Lymphoma Myeloma Leuk. 2020;20(10):661-7.
20. Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024;404(10466):1940-54.
21. Marshalek JP, Qing X, Dragan M, Tomassetti S. Retrospective study of CD20 expression loss in relapsed or refractory B-cell non-hodgkin lymphoma. J Hematol. 2024;13(6):268-77.
22. Ferreri AJ, Dognini GP, Verona C, Patriarca C, Doglioni C, Ponzoni M. Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma. Haematologica. 2007;92(1):e1-2.
23. Hwang JP, Feld JJ, Hammond SP, Wang SH, Alston-Johnson DE, Cryer DR, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):3698-715.
24. Vaidya R, Torres Lopez A, Awan F, Hrom J, Rivera-Rodriguez N, Lee EH, et al. ABCL-1224: Updated results from EPCORE NHL-6: phase 2 study of subcutaneous epcoritamab as outpatient treatment for 2L+ relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Clin Lymphoma Myeloma Leuk. 2025;25(supplement 1):S790-S1.
25. Falchi L, Hutchings M, Carlo-Stella C, Morschhauser F, Dickinson M, Cartron G, et al. Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma. Haematologica. 2025;110(4):999-1004.
26. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-38.
27. Crochet G, Iacoboni G, Couturier A, Bachy E, Iraola-Truchuelo J, Gastinne T, et al. Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma. Blood. 2024;144(3):334-8.
28. Melody M, Gordon LI. Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma. Haematologica. 2024;109(10):3138-45.

Ojjaara (momelotinib)
200 mg • 150 mg • 100 mg tablets

Discover OJJAARA for the treatment of splenomegaly and/or disease-related symptoms in your patients with

Intermediate or high-risk **PMF, PPV MF or PET MF**



moderate to severe **anemia**

OJJAARA is indicated for the treatment of splenomegaly and/or disease-related symptoms in adult patients with intermediate or high-risk primary myelofibrosis (PMF), post polycythemia vera (PPV) MF or post essential thrombocythemia (PET) MF who have moderate to severe anemia.[1]

Clinical use:

Pediatrics: Safety and efficacy in children and adolescents <18 years of age not established; therefore, OJJAARA is not indicated for pediatric use.

Geriatrics: No overall differences in safety or effectiveness have been observed between patients aged ≥65 years and younger patients.

Most serious warning and precautions:

Serious bacterial and viral infections: Reported, including fatal cases. Do not initiate treatment in patients with active infections, monitor patients receiving OJJAARA for infections and treat promptly.

Relevant warnings and precautions:

- Secondary malignancies
- Thrombosis, major adverse cardiovascular events (MACE)
- Caution driving and operating machinery
- Thrombocytopenia and neutropenia
- Hepatotoxicity
- Hepatitis B reactivation
- Blood cell counts, liver function test
- Fertility, teratogenic risk
- Use in pregnant or breast-feeding women
- Contains lactose monohydrate

For more information:

Please consult the Product Monograph at gsk.ca/OJJAARA/PM for important information relating to adverse reactions, drug interactions, and dosing. To request a Product Monograph or to report an adverse event, please call 1-800-387-7374.

MF, myelofibrosis; PET, post-essential thrombocythemia; PMF, primary myelofibrosis; PPV, post-polycythemia vera.

Reference:
1. OJJAARA Product Monograph. GlaxoSmithKline Inc.

Ojjaara GSK

MEMBER OF INNOVATIVE MEDICINES CANADA

REVIEWED BY PAAB

104385
03/25

doi.org/10.58931/cht.2025.4379

About the Author

Jesse Shustik, MD, FRCPC

Dr. Jesse Shustik is a hematologist-oncologist practicing at BC Cancer-Surrey Centre in British Columbia. His primary clinical interest is in lymphoid malignancies and multiple myeloma, and he has been active in myeloma clinical trials at his centre. He is the site representative for the Canadian Myeloma Research Group at his centre and has been a provincial lead for the BC Cancer myeloma program.

Affiliations: Department of Medical Oncology, BC Cancer-Surrey Centre, Surrey, B.C.

Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor

Jesse Shustik, MD, FRCPC

Introduction

Recent survival improvements in patients with multiple myeloma are attributable largely to the introduction of three main drug classes, immunomodulatory drugs (IMIDs), proteasome inhibitors, and anti-CD38 monoclonal antibodies.[1] However, the majority of patients will inevitably develop resistance to all three drug classes, and survival in this setting has been historically poor.[2-3]

Several novel therapeutic classes exploiting new mechanisms of action (e.g., chimeric antigen receptor (CAR)-T cell therapy, bispecific antibodies, antibody-drug conjugates (ADC), and selective inhibitors of nuclear export) have shown high levels of activity in relapsed myeloma and promise to transform the treatment landscape.[4-5] However, these therapies have been associated with distinct toxicity profiles, with adverse effects that are uncommonly observed with conventional antimyeloma therapies. Given improvements in long-term disease control and survival with current therapies, treatment-related toxicity represents an increasingly important health burden in patients with myeloma, and the development of effective toxicity management strategies is required to minimize complications and ensure preserved quality of life.

The current article focuses on unique toxicities associated with three agents that have obtained recent approval for use in relapsed myeloma: belantamab mafodotin, an anti-B cell maturation antigen (BCMA) antibody-drug conjugate (ocular toxicity); talquetamab, an anti- G protein–coupled receptor class C group 5 member D (GPRC5D) bispecific antibody (oral and cutaneous toxicity); and selinexor, a selective inhibitor of nuclear export (hematological, gastrointestinal, and constitutional toxicity). Key trials for these agents are summarized in **Table 1**.

Belantamab mafodotin

Belantamab mafodotin (belamaf) is a first-in-class, humanized ADC targeting B-cell maturation antigen, a cell surface receptor ubiquitously expressed on myeloma plasma cells.[5] Phase 1/2 studies of single-agent

belamaf demonstrated significant activity in relapsed/refractory myeloma, though with adoption complicated by frequent ocular toxicity and lack of benefit over standard of care in a randomized trial.[6-7] The pivotal DREAMM-7/DREAMM-8 phase 3 trials demonstrated the benefit of belamaf-containing combination regimens in patients with relapsed myeloma after 1 or more prior lines of therapy, in comparison with standard-of-care regimens.[8-9] In the DREAMM-7 study, BVd (belamaf, bortezomib, dexamethasone) was associated with significant prolongation of progression-free survival (PFS) in comparison with DVd (daratumumab, bortezomib, dexamethasone) (median PFS 36.6 vs 13.4 months; hazard ratio [HR]: 0.41), with evidence of overall survival benefit on updated follow-up.[8,10] In the DREAMM-8 study, BPd (belamaf, pomalidomide, dexamethasone) demonstrated significant improvement in PFS in comparison with the standard-of-care PVd regimen (pomalidomide, bortezomib, dexamethasone) (12-month estimated PFS, 71% vs. 51%; HR: 0.52).[9] The BVd/BPd regimens are approved by Health Canada for use in relapsed multiple myeloma, with specific indications following the eligibility criteria of the DREAMM-7/8 studies.

Corneal epithelial toxicity is a known effect of ADC therapy and occurs frequently in patients receiving belamaf. Common ocular symptoms include dry eye, photophobia, and reduction in visual acuity, and are associated with microcystic changes in the corneal epithelium on ocular slit lamp examination.[11] The exact mechanisms of ocular toxicity remain uncertain, but have been hypothesized to relate to off-target uptake of the ADC in corneal epithelial cells and resultant apoptosis due to intracellular release of the monomethyl auristatin F (MMAF) payload. The incidence of all-grade and grade 3-4 ocular toxicity has ranged from 70–90% and 30–55% of patients, respectively, in prospective belamaf single-agent and combination trials.[6,8-9,12] Of note, pre-existing ocular conditions (e.g., cataracts, glaucoma, baseline visual acuity >20/50) have not been exclusion criteria from belamaf trials, and an association between baseline ocular conditions and an increased risk of ocular adverse events has not been consistently observed.[8-9,13]

Serial ophthalmological examinations were mandatory for patients receiving belamaf-containing regimens on the DREAMM-7/8 studies, and ophthalmic findings were graded based on a Keratopathy and Visual Acuity (KVA) scale incorporating corneal findings on ocular slit lamp exam and measured changes in best corrected visual acuity (BCVA) (**Tables 2 and 3**).[8-9,14] Protocol-based dose modifications in both trials were primarily based on ophthalmic exam findings, with dose delays until resolution and/or dose reduction required for patients with grade ≥2 findings. Overall, dose delays due to ocular toxicity occurred in 78/75% and dose reductions in 44/57% of patients on BVd/BPd, respectively, with the majority of patients experiencing a first event after the first 2 cycles of therapy. Patients commonly experienced multiple episodes of ophthalmic toxicity, with approximately 55% of patients with a grade ≥2 ophthalmic event in both studies experiencing three or more occurrences. However, ocular toxicity was reversible with treatment interruption in the majority of patients. In a pooled analysis of both studies, documented resolution had occurred in 83% of grade ≥2 ophthalmic events at the time of data cut-off with a median time to resolution of 12 weeks.[14] In patients with reduction of visual acuity to 20/50 in the DREAMM-7/8 studies, 85–95% had improvement of vision to baseline acuity, with a median time to resolution of 8–9 weeks; improvement occurred in all patients with reduction of visual acuity to 20/200 (1-2% of belamaf-treated patients in both studies).[8-9,14] Discontinuation of therapy due to ocular toxicity occurred in 9% of patients in both trials.

Belamaf dose delays and modifications led to a progressive lengthening of treatment interval in the DREAMM-7/8 studies, though without appearing to compromise efficacy. In both studies, the median interval between doses increased over time, from the initial protocol-specified intervals of 3–4 weeks to 8–12 weeks after the first 9 months.[14] However, among patients treated with BVd experiencing at least one extended dose delay (>2 cycles), median PFS was 36.6 months, similar to the overall BVd arm in DREAMM-7, and in the DREAMM-8 study, the estimated 12-month PFS was 90% in BPd-treated patients requiring at least one extended dose delay. Among patients requiring extended belamaf dose delays, 85–90% had already achieved at least a partial response prior to the first extended dose delay, with up to 90% subsequently achieving at least very good partial response (VGPR) following the delay.

Practical guidelines have been created for the management of belamaf-associated ocular

Study	Study Type	Population	Treatment	Response rate	PFS	OS	Toxicity
DREAMM-7[8]	Phase 3, randomized, open-label	Relapsed MM, at least 1 prior line of therapy (n=494)	**Standard arm (DVd)** Bortezomib 1.3 mg/m^2 SC, d. 1,4,8,11/21-day cycle), 8 cycles Dexamethasone 20 mg PO, day of/day after each bortezomib dose, 8 cycles Daratumumab 16 mg/kg IV, qweek cycles 1–3, q3 weeks cycles 4-8, q4 weeks cycle 9+, until progression **Experimental arm (BVd)** Bortezomib, per standard arm (above) Dexamethasone, per standard arm (above) Belantamab mafodotin 2.5 mg/kg IV, d.1 of 21-day cycle, until progression	***BVd vs. DVd*** **ORR:** 83 vs. 71% **VGPR:** 66 vs 46% **CR:** 35 vs.17% **MRD-negative rate:** 39 vs. 17%	***Median PFS:*** **BVd:** 36.6 months **DVd:** 13.4 months (HR: 0.41, p<0.001)	***18-month OS:*** **BVd:** 84% **DVd:** 73% (HR: 0.57, p=NS)	***Thrombocytopenia, grade 3–4*** **BVd:** 55% **DVd:** 35% ***Infection, grade 3–4*** **BVd:** 31% **DVd:** 20% ***Ocular adverse events, any-grade*** **BVd:** 79% **DVd:** 29% ***Ocular adverse events, grade 3–4*** **BVd:** 34% **DVd:** 3%
DREAMM-8[9]	Phase 3, randomized, open-label	Relapsed MM, at least 1 prior line of therapy, with previous lenalidomide exposure (n=302)	**Standard arm (PVd)** Bortezomib 1.3 mg/m^2 SC, d. 1,4,8,11/21-day cycle, cycles 1-8, then d. 1,8/21-day cycle, cycle 9 onwards, until progression Pomalidomide 4 mg PO, d. 1–14/21-day cycles, until progression Dexamethasone, 20 mg PO, day of/day after each bortezomib dose, until progression **Experimental arm (BPd)** Belantamab mafodotin 2.5 mg IV cycle 1, then 1.9 mg/kg IV q 4 weeks, cycle 2 onwards, until progression Pomalidomide 4mg PO, d 1–21/28-day cycle, until progression Dexamethasone 40 mg PO weekly, until progression	***BPd vs. PVd*** **ORR:** 77 vs. 72% **VGPR:** 64 vs.38% **CR:** 40 vs.16% **MRD-negative rate:** 32 vs. 5%	***12-mo. PFS*** **BPd:** 71% **PVd:** 51% (HR: 0.52, p<0.001)	***12-mo. OS*** **BPd:** 83% **PVd:** 76% (HR 0.77, p=NS)	***Thrombocytopenia, grade 3-4*** **BPd:** 24% **PVd:** 20% ***Infection, grade 3–4*** **BPd:** 49% **PVd:** 26% ***Ocular, all-grade*** **BPd:** 89% **PVd:** 30% ***Ocular, grade 3–4*** **BPd:** 43% **PVd:** 2%

Study	Study Type	Population	Treatment	Response rate	PFS	OS	Toxicity
MonumenTAL-1[20]	Phase 1–2	Relapsed MM, at least 3 prior lines of therapy, including IMID, proteasome inhibitor, and anti-CD38 monoclonal antibody (n=375)	**Recommended Phase 2 dosing:** Talquetamab 0.4 mg/kg SC qweek **OR** Talquetamab 0.8 mg/kg SC q2weeks	***0.4 mg/kg q week:*** **ORR:** 74% **VGPR:** 59% **CR:** 33% ***0.8 mg/kg q2weeks:*** **ORR:** 69% **VGPR:** 59% **CR:** 40%	**Median PFS 0.4 mg/kg q week:** 7.5 months **0.8 mg/kg q2weeks:** 11.2 months	***12-month OS 0.4 mg/kg q week:*** 76% ***0.8 mg/kg q2weeks:*** 77%	***CRS:*** **all-grade:** 76% **grade 3-4:** 1.5% ***ICANS:*** **all-grade:** 8% **grade 3-4:** 2% ***Infection:*** **all-grade:** 64% **grade 3-4:** 19% ***Dysgeusia:*** **all-grade:** 72% ***Rash:*** **all-grade:** 35% **grade 3-4:** 3.5% ***Non-rash skin toxicity:*** **all-grade:** 65% **Grade 3-4:** 0.3% ***Nail-related:*** **all-grade:** 55.5 ***Weight loss:*** **all-grade:** 40% **grade 3-4:** 3%
BOSTON[26]	Phase 3, randomized, open-label	Relapsed MM, 1-3 prior lines of therapy	**Standard Arm: Vd** Bortezomib 1.3 mg/m^2 SC d.1,4,8,11/21-day cycle, cycles 1-8; 1.3 mg/m^2 SC d. 1,8,15,22/35-day cycle, cycle 9 onward, until progression Dexamethasone 20 mg PO day of/ after bortezomib, until progression **Experimental Arm: SVd** Selinexor 100 mg PO, d. 1,8,15,22,29/35-day cycle, until progression Bortezomib 1.3 mg/m^2 SC, d. 1,8,15,22/35-day cycle, until progression Dexamethasone 20 mg PO, day of/ after each bortezomib dose, until progression	***SVd vs. Vd*** **ORR:** 76 vs. 62% **VGPR:** 45 vs. 32% **CR:** 17 vs. 10%	***Median PFS:*** **SVd:** 13.9 months **Vd:** 9.5 months (HR: 0.7, p=0.0075)	***Median OS*** **SVd:** NR **Vd:**25 months (HR: 0.84, p=NS)	***Thrombocytopenia:*** **grade 3-4:** **SVd:** 39% **Vd:** 17% ***Neutropenia:*** **grade 3-4:** **SVd:** 9% **Vd:** #% ***Fatigue:*** **all-grade/grade 3–4:** **SVd:** 42/18% **Vd:** 13/1% ***Nausea:*** **all-grade/grade 3–4:** **SVd:** 50/10% **Vd:** 8/0% ***Diarrhea:*** **all-grade/grade 3–4:** **SVd:** 32/25% **Vd:** 6/1% ***Weight loss:*** **all-grade/grade 3–4:** **SVd:** 26/12% **Vd:** 2/1%

Table 1. Pivotal trials (belantamab mafodotin, talquetamab, selinexor); *courtesy of Jesse Shustik, MD, FRCPC.*

Abbreviations: BPd: belamaf, pomalidomide, dexamethasone; **BVd:** belamaf, bortezomib, dexamethasone; **CR:** complete response; **CRS:** cytokine release syndrome; **DVd:** daratumumab, bortezomib, dexamethasone; **HR:** hazard ratio; **ICANS:** immune cell-associated neurologic syndrome; **IMID:** immunomodulatory drug; **IV:** intravenous; **MM:** multiple myeloma; **MRD:** minimal residual disease; **NR:** not reached; **NS:** not significant; **ORR:** overall response rate; **OS:** overall survival; **PFS:** progression-free survival; **PVd:** pomalidomide, bortezomib, dexamethasone; **SC:** subcutaneous; **SVd:** selinexor, bortezomib, dexamethasone; **Vd:** bortezomib, dexamethasone; **VGPR:** very good partial response.

	DREAMM-7[8,14]	DREAMM-8[9,14]
Standard belamaf schedule	2.5 mg/kg IV q3 weeks	2.5 mg/kg IV cycle 1, then 1.9 mg/kg IV q4 weeks (cycle 2 onward)
Dose modification (reduced dose level 1)	1.9 mg/kg IV q3 weeks	1.9 mg/kg IV q8 weeks
Grade ≥2 OEF incidence	86%	87%
Median time to onset, first grade ≥2 OEF	6 weeks	5 weeks
Resolution rate, first grade ≥2 OEF	81%	86%
Time to resolution, first grade ≥2 OEF	12 weeks	16 weeks
Visual acuity reduction 20/50, incidence	34%	34%
Visual acuity reduction 20/200, incidence	2%	1%
Resolution rate, visual acuity reduction to 20/50	94%	84%
Time to resolution, visual acuity reduction 20/50	9 weeks	8 weeks
Proportion of time on study with visual acuity <20/50	11%	14%
Ocular toxicity leading to dose delay, incidence	78%	75%
Ocular toxicity leading to dose reduction, incidence	44%	57%
Ocular toxicity leading to discontinuation, incidence	9%	9%

Table 2. Belantamab-related ocular toxicity, DREAMM-7/8 studies.[8,9,15]

Abbreviations: IV: intravenous; **OEFs:** ophthalmic examination findings

toxicity (**Table 3**).[13] Multidisciplinary collaboration between treating physicians and eye care professionals remains an essential component of therapy, and should include shared education strategies, efficient communication pathways, and clear reporting templates for ophthalmic exam findings. Serial ophthalmological evaluation remains obligatory during early cycles of therapy. However, in patients without ongoing toxicity, a vision-related patient questionnaire incorporating ocular symptoms and effects on activities of daily living has been proposed as a screening tool for treating clinicians, eliminating the need for regular eye care specialist assessment in patients without symptoms. In a preliminary evaluation in patients treated in a prospective belamaf trial, patients

LILLY IS COMMITTED TO CANCER RESEARCH

At Lilly, we unite caring with discovery to create our medicines, with over 50 years of dedication to researching and developing medicines for a wide range of cancers.

We are committed to raising public awareness, supporting research and contributing to scientific advances in cancer research. **But our work isn't done.**

At Lilly, we are proud to be part of the oncology community and are excited about the future of cancer research. Learn more about our commitment to cancer research today.

NEVER MISS A LILLY UPDATE
Scan to subscribe to Lilly digital communications

Actor portrayal.

MEMBER OF INNOVATIVE MEDICINES CANADA

REVIEWED BY PAAB

	Examination findings per KVA scale	Recommended dose modifications
Grade 1	**Corneal examination finding(s)** • Mild superficial punctate keratopathy[a] **Change in BCVA[b]** • Decline from baseline of one line on Snellen Visual Acuity	• Continue according to belamaf prescribing information • Ophthalmic evaluation may be planned to confirm ocular event(s) do not worsen
Grade 2	**Corneal examination finding(s)** • Moderate superficial punctate keratopathy[c] **Change in BCVA[b]** • Decline from baseline of two or three lines (and Snellen Visual Acuity not worse than 20/200)	• Use Q8W dosing and maintain at new dose interval, provided recovery to Grade 1 • If ocular events remain Grade 2 after 8 weeks **OR** Grade 2 ocular events recur after initial recovery to Grade 1, consider extending dose interval to 12 weeks • If dose interval exceeds 12 weeks, reduce belamaf dosee
Grade 3	**Corneal examination finding(s)** • Severe superficial punctate keratopathy[d] **Change in BCVA[b]** • Decline from baseline by more than three lines (and Snellen Visual Acuity not worse than 20/200)	• Reduce belamaf dose[e] AND extend dose interval to at least 12 weeks and maintain at new dose interval, provided recovery to Grade 1 • If dose interval exceeds 16 weeks, further reduce belamaf dosee
Grade 4	**Corneal examination finding(s)** • Corneal epithelial defect **Change in BCVA[b]** • Snellen Visual Acuity worse than 20/200	• Consider treatment hold until Grade 1 • If continuing treatment with belamaf is being considered, reduce belamaf dose[e] AND extend dose interval to at least 12 weeks and maintain at new dose interval

Table 3. Recommended belamaf dose modifications following ocular events as defined by the KVA scale; *adapted from Terpos et al., 2024.*

[a] Mild superficial punctate keratopathy (documented worsening from baseline), with or without symptoms.
[b] Changes in visual acuity due to treatment-related corneal findings.
[c] Moderate superficial punctate keratopathy with or without patchy microcyst-like deposits, peripheral sub-epithelial haze (peripheral), or a new peripheral stromal opacity.
[d] Severe superficial punctate keratopathy with or without diffuse microcyst-like deposits involving the central cornea, sub-epithelial haze (central), or a new central stromal opacity.
[e] There are limited data on the efficacy of belamaf at doses lower than 1.9 mg/kg; if possible, the administration of doses below 1.9 mg/kg should be avoided.

Abbreviations: BCVA: best corrected visual acuity; **belamaf:** belantamab mafodotin; **KVA:** Keratopathy and Visual Acuity; **Q8W:** every 8 weeks.

monitored with a vision-related anamnestic tool exhibited no difference in rates of high-grade ocular toxicity compared to patients undergoing regular ophthalmological examination.[15] In the current Health Canada product monograph, ophthalmological examination is mandatory prior to each dose for the first 6 cycles of belamaf therapy, but may be reduced thereafter to every 3 months and whenever clinically indicated in patients without corneal or vision changes through the first 6 cycles.[16]

For prevention of ocular toxicity and management of low-grade symptoms, regular use of preservative-free lubricating drops and avoidance of contact lenses from the time of treatment initiation is advised. For grade ≥2

ophthalmic changes, current guidelines recommend dose delay until resolution and subsequent extension of the dosing interval to 8–12 weeks.[13] The use of more extended (8–12-week) belamaf dosing intervals as initial therapy has also been explored in recent combination studies and may become standard of care in the future.[12,17]

Talquetamab

Talquetamab is a first-in-class, humanized IgG4 bispecific antibody with binding to the CD3 receptor on T cells and to GPRC5D, an orphan transmembrane receptor with high levels of expression on malignant plasma cells but limited expression on normal plasma cells and other human tissues.[18] GPRC5D is highly expressed in the bone marrow of patients with myeloma and has been associated with high-risk disease features and adverse clinical outcomes. GPRC5D expression in normal tissues has been evaluated using sensitive analytic techniques, and in addition to plasma cells has been found in keratinized structures, including hair follicles, eccrine glands, and tongue.

In the first-in-human, phase 1–2 MonumenTAL-1 study, talquetamab was evaluated in a relapsed myeloma population with extensive previous treatment exposure, with a median of 6 prior lines of therapy, and 75% of patients triple-class-refractory to IMIDs, proteasome inhibitors, and anti-CD38 monoclonal antibodies.[19] In an updated analysis of patients treated at the recommended phase 2 doses (0.4 mg/kg subcutaneously weekly and 0.8 mg/kg subcutaneously every 2 weeks), the overall response rates (ORR) were 74% and 69% for the respective doses, with the majority of responders achieving VGPR or better, and similar rates were observed in a separate cohort of patients previously treated with anti-BCMA T-cell redirecting therapy.[20] Notably, the frequency of infectious complications and use of immunoglobulin replacement therapy was lower than that reported with anti-BCMA bispecific antibodies.

Toxicities associated with talquetamab include immunological events shared with other T cell-redirecting therapies (e.g., cytokine release syndrome [CRS], immune cell-associated neurologic syndrome [ICANS]), and unique 'on-target, off-tumour' toxicities likely related to GPRC5D expression on epithelial structures. Management of CRS/ICANS associated with talquetamab follows standard guidelines for T cell-redirecting therapies. Epithelial toxicities include oral, cutaneous, and nail effects; the incidence and temporal pattern of these toxicities are described in **Figure 1**. These are typically low-grade and rarely lead to treatment discontinuation, but may impact quality of life and require close management to ensure treatment adherence.[18,21]

Oral toxicity, including dysgeusia, dry mouth, and dysphagia, is commonly observed with talquetamab, with taste-related changes reported in approximately 75% of patients in the MonumentTAL-1 study.[20] The mechanism of dysgeusia as an on-target effect of talquetamab remains unclear, as GPRC5D expression on the tongue is limited to filiform papillae, which are not responsible for taste.[21] Taste changes typically develop within 1–2 months of initiation of therapy, are often persistent, and may be accompanied by clinically significant weight loss, occurring in approximately 40% of patients.[21] Various supportive therapies have been employed for dysgeusia, including steroid mouth rinses, zinc and biotin supplements, and salivary substitutes, though with limited evidence for efficacy. Talquetamab dose modifications have been suggested as the most effective mitigation strategy for oral toxicity.[18,21] Patients should be evaluated for oral comorbidities, including oral candidiasis, periodontal disease, and vitamin deficiencies leading to glossitis, and nutritional support may be required to minimize weight loss. In the MonumenTAL-1 study, weight loss was evident early, but with an overall stabilization or slight improvement over time, and cases of grade >3 weight loss (defined as >20% decrease from baseline weight) were rare.[20]

Cutaneous adverse events associated with talquetamab include skin rashes and "non-rash" skin toxicities, such as dry skin, pruritus, and skin exfoliation, most commonly affecting palms and soles.[21-22] Non-rash skin toxicities are more frequent, occurring in approximately two-thirds of patients, and require prophylactic or early use of emollients (e.g., ammonium lactate 12% or urea 10% cream) and sunscreen use for patients with photosensitivity. Skin rashes typically occur within the first month of therapy and resolve in most cases with the use of antihistamines, low-medium-potency topical corticosteroids, or short courses of oral corticosteroids for more extensive rashes. For persistent rashes,

Oral AEs	**Dysgeusia[1]** Incidence: 72.3% Grade 3/4: N/A Time to onset: 13–20 days Resolved: 38.3% Discontinuation: 0.6%	**Dysphagia** Incidence: 24.2% Grade 3/4: 0.9% Time to onset: 21–29 days Resolved: 65.9% Discontinuation: 0%	**Dry mouth** Incidence: 36.0% Grade 3/4: 0% Time to onset: 19–26 days Resolved: 39.0% Discontinuation: 0%
Skin and nail-related AEs (rash and no rash)	**Skin Rash[4]** Incidence: 34.8% Grade 3/4: 3.5% Time to onset: 20-27 days Resolved: 78.9% Discontinuation: 0%	**Skin Non-rash[6]** Incidence: 65.2% Grade 3/4: 0.3% Time to onset: 26-30 days Resolved: 59.4% Discontinuation: 0.9%	**Nail-related AEs[5]** Incidence: 55.5% Grade 3/4: 0% Time to onset: 64-69 days Resolved: 29.5% Discontinuation: 0%
Weight decrease Incidence: 39.5%[2] Grade 3/4: 3.2% Time to onset: 87-91 days[3] Resolved: 38.7% Discontinuation: 0.9%			

Figure 1. Summary of key AEs associated with talquetamab; *adapted from Chari et al, 2024; http://creativecommons.org/licenses/by/4.0/*

[1]Includes dysgeusia, ageusia, hypogeusia, and general taste disorders.
[2]The number of patients with a ≥ 10% decrease in weight from baseline in the 0.4 mg/kg QW, 0.8 mg/kg Q2W, and prior T-cell redirection cohorts was 37.1%, 32.4%, and 29.4%, respectively.
[3]Time to onset for weight loss is reported for patients with a ≥ 10% decrease in weight from baseline.
[4]Includes rash, maculopapular rash, erythematous rash, and erythema.
[5]Includes nail discoloration, nail disorder, onycholysis, onychomadesis, onychoclasis, nail dystrophy, nail toxicity, and nail ridging.
[6]Includes skin exfoliation, dry skin, pruritus, and palmar-plantar erythrodysesthesia syndrome

Abbreviations: AE: adverse event; **CRS:** cytokine release syndrome; **ICANS:** immune effector cell-associated neurotoxicity syndrome; **QW:** weekly; **Q2W:** every other week.

a dermatology referral for consideration of skin biopsy may be warranted. Nail-related changes occur in 50–60% of patients and commonly persist for the duration of therapy, though rarely lead to dose modification or discontinuation.

Overall, dose modifications were infrequent for oral (7% of patients), skin (5%), and nail (1%) toxicities in the MonumenTAL-1 study, and treatment discontinuation occurred in only 2% of patients collectively for oral and dermatological toxicity.[20-21] However, despite supportive therapies described above, reductions in talquetamab dose or treatment frequency have been suggested as the most effective measure to ensure long-term treatment tolerability in patients with significant oral or cutaneous adverse events.[21] In a MonumenTAL-1 sub cohort, patients achieving at least a partial response prospectively underwent a reduction in talquetamab dose or extended treatment interval; despite dose reductions, all patients maintained responses, with a trend toward reduction in skin and oral toxicities.[23] The development of more refined toxicity grading systems and rational dose modification strategies is currently considered an area of high priority.[18,21]

Selinexor

Selinexor is an oral, first-in-class selective inhibitor of nuclear export with established activity in multiple myeloma. Its mechanism of action is based on inhibition of exportin 1 (XPO1), a nuclear export protein responsible for the traffic of over 200 "cargo proteins" from the cell nucleus to cytoplasm, leading to retention of tumour suppressor proteins in the nucleus and blockade of oncoprotein mRNA transfer to the cytoplasm.[24] Although initial use was based on studies demonstrating ORRs of 25–30% (in combination with dexamethasone alone) in heavily-pretreated patient populations, subsequent development of selinexor has focused on multidrug combination therapy with use in earlier treatment lines.[24-25] In the phase 3 BOSTON trial, weekly selinexor in combination with bortezomib-dexamethasone (SVd) demonstrated statistically higher ORR (76% vs. 62%), ≥VGPR (45 vs. 32%), and median PFS (13 vs. 9.5 months; HR: 0.7; p=0.0075) in comparison with a standard therapy arm of twice-weekly bortezomib-dexamethasone (Vd), in patients with relapsed multiple myeloma after 1–3 prior lines of therapy.[26] Current Health Canada approval of selinexor is for use in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Selinexor has a distinct toxicity profile that includes hematological (thrombocytopenia, neutropenia), gastrointestinal (nausea, diarrhea), and constitutional adverse effects (fatigue, anorexia, weight loss), leading to high rates of early treatment discontinuation in initial studies.[24-25] While these studies employed a more intensive twice-weekly dosing schedule, the use of weekly selinexor dosing was evaluated in subsequent multiagent combination regimens, leading to a chosen selinexor dose of 100 mg weekly in the phase 3 BOSTON study. By consensus, weekly selinexor dosing has reduced the severity of adverse effects,[27] though previous toxicities are still commonly observed. In the BOSTON study, toxicities occurring with higher frequency in the SVd arm included thrombocytopenia (all-grade/grade 3–4: 60/39%), neutropenia (35/9%), nausea (50/8%), vomiting (30/4%), diarrhea (32/6%), fatigue (42/13%), anorexia (35/4%), and weight loss (26/2%).[26]

Aggressive supportive care and liberal dose reduction are the mainstays of selinexor toxicity management, and physician comfort with both strategies is likely to be associated with improved treatment adherence and outcomes.[27-28] Key supportive measures are described below. Although the starting selinexor dose in the BOSTON study was 100 mg weekly, the majority of patients in the SVd arm (65%) required dose reduction, leading to an actual median selinexor dose of 80 mg weekly in this study. In a post-hoc analysis, patients treated with SVd undergoing selinexor dose reduction had improved outcomes in comparison with those who did not (median PFS: 16.6 vs. 9.2 months).[29] In clinical practice, lower weekly doses of selinexor (i.e., 40–80 mg weekly) are commonly effective, and may be justified as initial therapy in the majority of patients. Notably, more recent combination studies with pomalidomide or carfilzomib backbones have employed selinexor doses ranging from 40–80 mg weekly, with promising efficacy.[30-31]

Thrombocytopenia represents the most common hematological toxicity associated with selinexor and has been attributed to inhibition of thrombopoietin signalling during early megakaryopoiesis. The kinetics of selinexor-associated thrombocytopenia are unique, typically occurring 2–3 weeks after treatment, resulting in an approximately 50% reduction in platelet counts, and resolving within 1–2 weeks after drug interruption.[24,27] The use of thrombopoietin agonists or platelet transfusions was required in approximately one-quarter of patients in the BOSTON study, but clinically significant bleeding events were rare.[26] Current guidelines recommend dose reduction for patients with platelet counts of <50,000 and treatment interruption for patients with platelet counts of <25,000, though additional caution may be required in patients with additional bleeding risks, such as concurrent anticoagulant use.[27]

Selinexor-associated nausea is believed to relate to central nervous system effects from drug passage across the blood-brain barrier and requires aggressive antiemetic prophylaxis during initiation of therapy. Routine prophylaxis with an NK-1 inhibitor in addition to a 5-HT3 antagonist (e.g., aprepitant plus ondansetron, netupitant-palonosetron) should now be considered standard; in patients with ongoing nausea or restricted access to NK-1 inhibitors, prophylaxis with olanzapine (2.5–5 mg in the evening for 1–3 days after selinexor) may also be used.[27] The incidence of nausea decreases significantly after the first two months of therapy, and may allow tapering of the antiemetic regimen.

Other frequent nonhematological toxicities include anorexia and fatigue, which may be high-grade in nature. Reduction in oral intake may be associated with weight loss and dehydration, and close nutritional monitoring with high-caloric supplementation and maintenance of adequate oral fluid intake (at least 2L daily) are advised.[27] Hyponatremia occurs frequently and requires close laboratory monitoring during initial cycles, with correction by sodium chloride tablets if present. Fatigue may respond to nutritional optimization and treatment of gastrointestinal toxicities, but for persistent fatigue, the use of methylphenidate has had reported benefit.

Conclusion

Belantamab mafodotin, talquetamab, and selinexor are novel targeted therapies with proven activity in relapsed multiple myeloma and represent attractive treatment options in patients with relapse after treatment with IMIDs, proteasome inhibitors, and/or anti-CD38 monoclonal antibodies. Although these agents are associated with distinct adverse effect profiles, discontinuation due to toxicity is only required in a minority of patients, and further dose optimization after initial approval and increased clinician experience with use are also likely to improve treatment delivery and outcomes. The use of these agents may further evolve as new drug combinations, use in earlier lines of therapy, and fixed-duration approaches are explored.

Correspondence

Jesse Shustik, MD, FRCPC
Email : jshustik@bccancer.bc.ca

Financial Disclosures

J.S.: None declared.

References

1. Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10(1):45. doi: 10.1038/s41572-024-00529-7.
2. Visram A, De La Torre A, White D, Su J, Masih-Khan E, Chu M, et al. Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database. Blood Cancer J. 2023;13(1):181. doi: 10.1038/s41408-023-00946-z.
3. Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36(5):1371-1376. doi: 10.1038/s41375-022-01531-2.
4. Van de Donk NWCJ, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet. 2023;402(10396):142-158. doi: 10.1016/S0140-6736(23)00521-4..
5. Neri P, Leblay N, Lee H, Gulla A, Bahlis NJ, Anderson KC. Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. Nat Rev Clin Oncol. 2024;21(8):590-609. doi: 10.1038/s41571-024-00913-y.
6. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0.
7. Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al.. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801-e812. doi: 10.1016/S2352-3026(23)00243-0.
8. Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ,et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(5):393-407. doi: 10.1056/NEJMoa2405090.
9. Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab Mafodotin, Pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024;391(5):408-421. doi: 10.1056/NEJMoa2403407..
10. Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: overall survival analysis and updated efficacy outcomes of the phase 3 Dreamm-7 trial. Blood 2024;144(Supplement 1):772.

11. Lee V, Hultcrantz M, Petrone S, Lewis EW, Banna H, Lichtman E, et al. Characterization of belantamab mafodotin-induced corneal changes in patients with multiple myeloma. JAMA Ophthalmol. 2025;143(6):507-514. doi: 10.1001/jamaophthalmol.2025.1008.
12. Trudel S, McCurdy A, Louzada ML, Parkin S, White D, Chu MP, et al. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nat Med. 2024;30(2):543-551. doi: 10.1038/s41591-023-02703-y.
13. Terpos E, Trudel S, Mateos MV, Alejandre N, Colby K, Dimopoulos MA, et al. Practical guidance on clinical management of belantamab mafodotin-associated ocular events. Am J Hematol. 2025;100(10):1839-1850. doi: 10.1002/ajh.70015.
14. Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, et al. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025:bloodadvances.2025016949. doi: 10.1182/bloodadvances.2025016949. Epub ahead of print.
15. E. Terpos, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, et al., Evaluation of a novel method guiding belantamab mafodotin dosing in multiple myeloma based on a patient-reported questionnaire. 2024 ASCO Annual Meeting; Abstract 7530.
16. BLENREP Product Monograph; Date of Authorization: September 26th, 2025; https://ca.gsk.com/media/j3dnbhae/blenrep.pdf
17. Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, et al. Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study. Haematologica. 2024;109(8):2594-2605. doi: 10.3324/haematol.2023.284347.
18. Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024;14(1):24. doi: 10.1038/s41408-023-00966-9.
19. Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232-2244. doi: 10.1056/NEJMoa2204591.
20. Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol. 2025;12(4):e269-e281. doi: 10.1016/S2352-3026(24)00385-5.
21. Chari A, Krishnan A, Rasche L, Ye JC, Garfall A, Popat R, et al. Clinical management of patients with relapsed/refractory multiple myeloma treated with talquetamab. Clin Lymphoma Myeloma Leuk. 2024;24(10):665-693.e14. doi: 10.1016/j.clml.2024.05.003.
22. Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, Gállego Pérez-Larraya J, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25(5):e205-e216. doi: 10.1016/S1470-2045(24)00043-3.
23. Chari A, Oriol A, Krishnan A, et al. Efficacy and safety of less frequent/lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma: results from the phase 1/2 MonumenTAL-1 study. Blood 2023;142(suppl 1):1010.
24. Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020;34(9):2430-2440. doi: 10.1038/s41375-020-0756-6.
25. Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727-738. doi: 10.1056/NEJMoa1903455.
26. Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563-1573. doi: 10.1016/S0140-6736(20)32292-3.
27. Nooka AK, Costa LJ, Gasparetto CJ, Richardson PG, Siegel DS, Chari A, et al. Guidance for use and dosing of selinexor in multiple myeloma in 2021: consensus from International Myeloma Foundation expert roundtable. Clin Lymphoma Myeloma Leuk. 2022;22(7):e526-e531. doi: 10.1016/j.clml.2022.01.014.
28. Mikhael J, Noonan KR, Faiman B, Gleason C, Nooka AK, Costa LJ, et al. Consensus recommendations for the clinical management of patients with multiple myeloma treated with selinexor. Clin Lymphoma Myeloma Leuk. 2020;20(6):351-357. doi: 10.1016/j.clml.2019.12.026.
29. Jagannath S, Delimpasi S, Grosicki S, Van Domelen DR, Bentur OS, Špička I, et al. Association of selinexor dose reductions with clinical outcomes in the BOSTON study. Clin Lymphoma Myeloma Leuk. 2023;23(12):917-923.e3. doi: 10.1016/j.clml.2023.08.018.
30. Gasparetto C, Schiller GJ, Tuchman SA, Callander NS, Baljevic M, Lentzsch S, et al. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. Br J Cancer. 2022;126(5):718-725. doi: 10.1038/s41416-021-01608-2.
31. White DJ, Chen CI, Baljevic M, et al. Once weekly oral selinexor, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma. Blood 2021;138:2748.

DARZALEX® SC
daratumumab subcutaneous

Consider a DARZALEX® SC based regimen for your ASCT-eligible, newly diagnosed multiple myeloma patients[1]

DARZALEX® SC (daratumumab injection) is indicated in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.[1]

DATA FROM THE PERSEUS STUDY (phase 3, open-label, randomized study in transplant-eligible NDMM patients): DARZALEX® SC + VRd (n=355) vs. VRd alone (n=354)[1]

Primary PFS analysis at 47.5 months (primary endpoint; HR=0.42; 95% CI: 0.30, 0.59; $p<0.0001$)[1]

- Number of PFS events: DARZALEX® SC + VRd 14.1% (n=50/355) vs. VRd 29.1% (n=103/354)[1]

Select findings from the first interim analysis:
During maintenance treatment, 207 (59%) patients discontinued DARZALEX® SC after completing at least 24 months of maintenance treatment and achieving MRD negativity that was sustained for at least 12 months.[1]

Please refer to the Product Monograph for the complete dosing information.

Clinical use:
- No overall differences in effectiveness were observed between elderly (≥65 years of age) and younger patients. Some differences in clinical safety have been identified between elderly and younger patients. No dose adjustments are considered necessary in elderly patients. The safety and efficacy of DARZALEX® SC have not been established in patients with AL amyloidosis with advanced cardiac disease (Mayo Stage IIIB or NYHA Class IIIB or IV).
- DARZALEX® SC is not authorized for pediatric use.

Relevant warnings and precautions:
- Risk of neutropenia/thrombocytopenia when used in combination with background therapy
- DARZALEX® SC monotherapy increases neutropenia; monitor CBC periodically during DARZALEX® SC treatment when used in combination with background therapies; DARZALEX® SC increases neutropenia and thrombocytopenia induced by background therapies; monitor patients with neutropenia for signs of infection
- Administration-related reactions, including anaphylactic reactions
- Hypogammaglobulinemia
- Infections
- Risk of hepatitis B virus (HBV) reactivation
- Interference with indirect antiglobulin test (Indirect Coombs test); patient's blood should be typed and screened prior to starting DARZALEX® SC
- Interference with determination of complete response and of disease progression in some patients with IgG kappa myeloma protein
- Pregnant women or women in their childbearing years
- Breastfeeding
- Hepatic impairment
- Renal impairment
- Risk of fetal harm, the presence and transmission in sperm and blood, and prohibitions against blood and/or sperm donation when used in combination therapy
- The prescribing information for all medications used in combination with DARZALEX® SC must be consulted before starting therapy
- Risk of serious or fatal cardiac adverse reactions in patients with AL amyloidosis

For more information:
Please consult the Product Monograph at innovativemedicine.jnj.com/canada/our-medicines for important information relating to adverse reactions, drug interactions, and dosing that has not been discussed in this piece.

The Product Monograph is also available by calling 1-800-567-3331.

SC=subcutaneous; ASCT=autologous stem cell transplant; NDMM=newly diagnosed multiple myeloma; VRd=Velcade® (bortezomib) + Revlimid® (lenalidomide) + dexamethasone; PFS=progression-free survival; HR=hazard ratio; CI=confidence interval; MRD=minimal residual disease; AL=amyloid light-chain; NYHA=New York Heart Association; CBC=complete blood count; IgG=immunoglobulin G; D-VRd=DARZALEX® (daratumumab) + Velcade® (bortezomib) + Revlimid® (lenalidomide) + dexamethasone.

PERSEUS Study parameters: A phase 3, open-label, multicentre, randomized study in patients with NDMM who were eligible for ASCT. Patients were randomized 1:1 to receive D-VRd or VRd. All patients received VRd in six 28-day cycles (four induction and two consolidation). VRd consisted of subcutaneous bortezomib (1.3 mg/m^2 of body-surface area on Days 1, 4, 8, and 11 of each cycle), oral lenalidomide (25 mg on Days 1 through 21 of each cycle), and oral or intravenous dexamethasone (40 mg on Days 1 through 4 and Days 9 through 12 of each cycle). Patients in the D-VRd group also received subcutaneous daratumumab (1800 mg per week during cycles 1 and 2; 1800 mg every 2 weeks during cycles 3 through 6). Within 6 weeks after the completion of induction therapy, patients underwent ASCT. Consolidation therapy began 30 to 60 days after transplantation, after which all patients received oral lenalidomide (10 mg per day, with the dose increased to 15 mg per day after three cycles at the investigator's discretion) in 28-day maintenance cycles until disease progression or unacceptable toxicity. Patients in the D-VRd group also received subcutaneous daratumumab (1800 mg every 4 weeks) until disease progression or unacceptable toxicity.[1,2]

References: 1. DARZALEX® SC (daratumumab injection) Product Monograph. Janssen Inc. November 27, 2024. **2.** Sonneveld P, *et al.* Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med* 2024;390(4):301–313.

Johnson&Johnson 19 Green Belt Drive | Toronto, Ontario | M3C 1L9 | **innovativemedicine.jnj.com/canada**

MEMBER OF INNOVATIVE MEDICINES CANADA
REVIEWED BY PAAB
Johnson&Johnson

About the Authors

Oksana Prokopchuk-Gauk, MD, FRCPC, DRCPSC

Dr. Oksana Prokopchuk-Gauk is the Provincial Transfusion Medicine Clinical Lead with the Saskatchewan Health Authority and an adult hematologist with the Saskatchewan Bleeding Disorders Program based at Royal University Hospital, Saskatoon. Dr. Prokopchuk-Gauk actively participates in provincial and national transfusion medicine committees, including the National Advisory Committee on Blood and Blood Products. Her research interests include identifying strategies to improve transfusion safety and blood utilization, and optimizing perioperative care in patients with inherited bleeding disorders.

Affiliations: Department of Pathology and Lab Medicine, Saskatchewan Health Authority; College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan.

Kathryn E. Webert, MD, MSc, FRCPC

Dr. Kathryn Webert is a Medical Director and Special Advisor with Canadian Blood Services and an Associate Professor with the Department of Pathology and Molecular Medicine at McMaster University in Hamilton, Ontario. Dr. Webert's clinical interests include transfusion medicine, benign hematology, and hemostasis and coagulation. Dr. Webert's areas of research interest include the utilization of blood and blood products and bleeding in patients with bone marrow failure.

Affiliations: Canadian Blood Services and Division of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario.

Jennifer Grossman, MD, FRCPC

Dr. Grossman is a Hematologist with the Department of Medicine and Assistant Professor at the University of Calgary. Following her hematology residency, she completed a Fellowship in adult primary immune deficiencies at the National Institutes of Health in Bethesda, Maryland. Dr. Grossman launched a clinic specifically for this patient population in Calgary, which has evolved to become the Collaborative Immunohematology Program, and includes the Subcutaneous Immunoglobulin program.

Affiliations: Division of Hematology and Hematologic Malignancies, University of Calgary, Calgary, Alberta.

doi.org/10.58931/cht.2025.4380

Rational Use of Immunoglobulin in Adult Patients with Secondary Hypogammaglobulinemia in the Setting of Hematologic Malignancy: A Canadian Perspective

Oksana Prokopchuk-Gauk, MD, FRCPC, DRCPSC
Kathryn Webert, MD, MSc, FRCPC
Jennifer Grossman, MD, FRCPC

Introduction

Hypogammaglobulinemia is identified by the detection of low serum immunoglobulin (Ig) levels. Secondary hypogammaglobulinemia (SHG) is an acquired state in which circulating Ig levels are reduced due to suppressed antibody production or increased antibody loss.[1,2] Specifically, SHG most commonly refers to low circulating total IgG levels. In contrast, primary hypogammaglobulinemia (PHG) is due to an underlying inborn error of immunity contributing to low or defective Ig production and frequent and/or severe infections.

In patients with hematologic malignancies, it is important to evaluate baseline Ig (IgG, IgM, IgA) levels at the time of diagnosis. However, it may be challenging to distinguish whether low Ig levels are attributable to PHG or SHG, if antibody defects are identified in the context of hematologic malignancies (including chronic lymphocytic leukemia [CLL], lymphoma, and multiple myeloma), even before initiation of immunosuppressive treatment,[3] PHG should be considered, especially in younger patients presenting with a hematologic malignancy who have a history of recurrent, severe infections.[1,3]

Treatment of several hematologic malignancies includes anti-CD20 B cell-depleting therapy, which is known to cause the development of SHG. Advancements in lymphoma and myeloma management now incorporate bispecific antibody therapies and chimeric antigen receptor T-cell (CAR T-cell) therapies, which have revolutionized care for patients with disease refractory to conventional treatments. However, the risk of SHG is significant, with rates of ≥70% with bispecific antibody treatments and 20–46% with CAR T-cell therapies.[4,5] Thus, patients with hematologic malignancies have a high rate of SHG attributable to both the underlying disease and associated treatment.

Pooled immunoglobulin products, including intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg), are a source of exogenous IgG that can be administered to replace IgG in patients who have deficient levels. Due to a continuing increase in global demand and a supply dependent on volunteer human donors (most of whom are compensated financially), it is prudent to ensure appropriate stewardship of Ig products. Canada has the third largest consumption of Ig per capita, narrowly trailing behind Australia and the United States,[6] with the annual demand of all countries continuing to increase. Supply sufficiency is a real concern for Canadians who are dependent on American donors and Ig manufacturers to provide approximately 75%–80% of the Ig utilized for patient care.[7]

In this context, we aim to provide a concise summary of when Ig may be considered for the management of SHG in adult patients with hematologic malignancies. Further, we highlight potential risks of adverse reactions due to Ig, the challenges with health system cost and global Ig supply constraints, and areas where further research is required.

Measured serum IgG level

Hypogammaglobulinemia: measured serum total IgG level <7 g/L
• Total IgG level subcategory stratification:
  ◦ IgG 4.0–6.9 g/L
  ◦ IgG 2.0–3.9 g/L
  ◦ IgG <1.9 g/L
• Evaluation of IgG subclasses is not recommended
Duration of low IgG levels subcategory stratification:
• Transient: 3–6 months, 6–12 months, or 12–24 months
• Persistent: more than 24 months

Clinically significant infections:
***Severe infection*—an infection requiring:** • An emergency room visit or hospitalization, and • Intravenous antibiotics, or • A prolonged course or more than 1 course of antibiotic/antiviral/antifungal therapy for the purposes of treatment (not prophylaxis). ***Recurrent* – any of the following occurring in 1 year:** • ≥2 new ear infections, or • ≥2 new sinus infections in the absence of allergy, or • ≥1 pneumonia (for more than 1 year), or • Deep abscesses of the skin or internal organs.

Table 1. Proposed definition of SHG, based on serum IgG levels and clinical infection frequency in adults.[1,8]

SHG Definition

There is a prominent lack of a standardized definition of SHG in the literature, which leads to difficulty in interpreting reported rates of SHG. Serum immunoglobulins that may be measured include IgG (total; subclasses may also be measured), IgA, IgM, and IgE. At present, only IgG-containing replacement therapies are available in Canada. In the context of SHG, limited evidence exists regarding the clinical impact and management strategies of acquired deficiencies of IgG subclasses, as well as total IgA and IgM levels.[1]

In 2022, a standardized definition of SHG, specifically referring to low serum IgG levels and criteria for clinical infection, was proposed by the American Academy of Allergy, Asthma, and Immunology (AAAAI) Primary Immunodeficiency and Altered Immune Response Committees to aid in standardizing future work.[1] Based heavily on primary immunodeficiency (PID) literature, these are summarized in **Table 1**. The listed criteria for severe and recurrent infection are adapted from the Jeffery Modell Foundation's *10 Warning Signs of Primary Immunodeficiency in Adults*, rather than in pediatrics.

In addition to Ig production, vaccination testing has been used as a functional test of the humoral immune system, in which serotype titers are measured before and 4–6 weeks after vaccination. As a pure polysaccharide vaccine, the polyvalent pneumococcal vaccine (Pneumovax 23) has been recognized as provoking a T cell-independent response and has long been used by immunologists.

Unfortunately, Pneumovax 23 is gradually being replaced by a protein-polysaccharide vaccine (Prevnar 20) in many countries, which does not evoke the same type of humoral response. Most other common vaccines, including those against diphtheria and tetanus, are protein-polysaccharide conjugate vaccines and therefore not useful in strictly assessing humoral response. The immunology community is still grappling with how to address this impending void in functional testing.[9]

In the context of SHG due to hematologic malignancy, vaccination testing is not routinely performed. If there is uncertainty around the patient's immune function and vaccination testing is a consideration, consultation with an immunology specialist is recommended.

Ig Replacement Therapy

The decision regarding when to start Ig replacement therapy (IgRT) in the setting of SHG varies, as there are no clear criteria as to when it should be initiated. Published recommendations generally recommend consideration of multiple patient factors, including low IgG levels and a history of serious or recurrent bacterial infections.[1,2] There is no evidence to support the use of IgRT in patients with low IgM or IgA in the context of a hematologic malignancy. It is important to make the distinction between bacterial and viral infections, as the efficacy of IgRT in preventing viral infections has not been proven.[10]

IgRT may include subcutaneous Ig (SCIg) or intravenous Ig (IVIg), and the decision regarding the administration modality must be considered based on resource availability, cost, and individualized patient factors. The cost of IVIg and SCIg is relatively equivalent per gram of IgG. SCIg self-administration at home may be a more convenient option for the patient and has been demonstrated to have a markedly lower health system cost impact than IVIg infusions in an ambulatory care setting, with the average administrative cost of SCIg per patient year being about $5,500 lower than IVIg administered in a hospital clinic.[11] A shared decision-making approach between the patient and multidisciplinary clinical care team is essential, given that the decision to initiate IgRT can be complex.[1]

There is even less clarity around the decision to initiate IgRT as primary versus secondary infection prophylaxis.[1,2] With the advances in hematologic malignancy treatments for relapsed and refractory disease, it remains unclear whether Ig should be initiated as a means of primary infection prophylaxis (i.e., before the development of any infections in the setting of documented low IgG levels), or if daily antibiotics may confer an equivalent protection in certain settings.[12] IgRT has most commonly been used for secondary prophylaxis (ie, to prevent additional severe or recurrent infection development), though proposed criteria to standardize IgRT eligibility based on IgG levels and clinically significant infection have been relatively recent.[1,8] Furthermore, if IgRT is initiated, an optimal IgG level required to achieve adequate infection prophylaxis has not been determined, especially if Ig is initiated prior to the development of a clinically significant infection.[2]

The half-life of total IgG from IVIg administration has been reported to be 26 days[13]; thus, it is not fully eliminated until at least 5 months after administration. Following baseline serum Ig monitoring at the time of disease diagnosis, monitoring of trough IgG levels should occur immediately prior to the next IVIg administration, or at any time during SCIg administration (steady-state) levels. Although a precise target IgG level in this context has not been defined, extrapolating from PID literature, an IgG level of 7–8 g/L is likely reasonable to mitigate against severe or recurrent bacterial infection. Expert opinion suggests that an even lower target trough IgG level in some patients with SHG may be adequate.

Assessment of individual patient factors is necessary to determine when a trial of an IgRT taper or discontinuation may be undertaken. To determine the endogenous patient Ig baseline, circulating Ig levels should be checked no sooner than 3 months following the last IgG dose. By 6 months after the last Ig dose, all replacement IgG will have been eliminated to reflect the patient's baseline Ig levels.[14]

Within Canadian jurisdictions, evidence-based clinical criteria for accessing IgRT have been developed to improve stewardship of this publicly funded resource. A summary of clinical criteria for accessing IgRT in the setting of SHG with hematologic malignancies is presented in **Table 2**.[15-19] A reference comparison of clinical criteria from Australia and the United Kingdom is included in **Table 3**.[20-21] All clinical criteria documents endorse using adjusted body weight (ABW) IgRT dosing.

Ig Preparations and Procurement

Human-source, purified preparations predominantly contain a polyclonal blend of IgG (no clinically significant replacement amount of IgM or IgA protein is included in preparations of IgRT available in Canada). The decision to initiate IVIg versus SCIg depends on the clinical indication for which IgRT is necessary, patient values, an informed discussion about the risks and benefits, and the administration modality related to each product. All brands of IVIg and SCIg available in Canada are approved for IgG replacement in the setting of SHG in adults.

First bispecific antibody indicated in the treatment of the triple-class exposed patients with R/R MM[1,2*]

TECVAYLI® has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization.[1]

TECVAYLI® (teclistamab injection) is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received ≥3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.[1]

TURN TO THE POWER OF
TECVAYLI®

Efficacy profile investigated in the open-label MajesTEC-1 trial:[1¶§]



Adapted from TECVAYLI® Product Monograph[1]

Clinical use:

Pediatrics (<18 years of age): not authorized for pediatric use.

Most serious warnings and precautions:

Cytokine release syndrome (CRS): can occur in patients receiving TECVAYLI®, including life-threatening or fatal reactions. Initiate treatment with TECVAYLI® step-up dosing schedule to reduce the risk of CRS. Monitor patients for signs or symptoms of CRS. Withhold TECVAYLI® until CRS resolves, provide supportive care and treatment as needed, or permanently discontinue based on severity.

Serious or life-threatening neurologic toxicities: can occur following treatment with TECVAYLI®, including immune effector cell-associated neurotoxicity syndrome (ICANS). The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Monitor patients for signs or symptoms of neurologic toxicity, including ICANS, during treatment. Withhold TECVAYLI® until neurologic toxicity resolves or permanently discontinue based on severity.

Other relevant warnings and precautions:

- Driving and operating machinery during and for 48 hours after completion of TECVAYLI® step-up dosing schedule and in the event of new onset of any neurological symptoms
- Hypogammaglobulinemia
- Neutropenia and febrile neutropenia
- Severe, life-threatening, or fatal infections
- New/reactivated viral or opportunistic infections
- Progressive multifocal leukoencephalopathy (PML), which can be fatal
- Hepatitis B virus reactivation
- Immune response to vaccines may be reduced
- Neurologic toxicities
- Live viral vaccines are not recommended
- Not recommended for women who are pregnant or breastfeeding
- Patients should use effective contraception

For more information:

Please consult the Product Monograph at innovativemedicine.jnj.com/canada/our-medicines for important information relating to contraindications, adverse reactions, drug interactions, and dosing/administration that has not been discussed in this piece.

The Product Monograph is also available by calling 1-800-567-3331.

R/R MM=relapsed/refractory multiple myeloma; CD38=cluster of differentiation 38; CI=confidence interval; CRS=cytokine release syndrome; HBV=hepatitis B virus; IRC=Independent Review Committee; IMWG=International Myeloma Working Group; PML=progressive multifocal leukoencephalopathy; PR=partial response; Q2W=every 2 weeks; SC=subcutaneous; sCR=stringent CR; CR=complete response; VGPR=very good PR.

* Comparative clinical significance unknown.

† Phase 1/2, single arm, open-label, multicentre study in adults with R/R MM who had received ≥3 prior therapies, including a proteasome inhibitor, immunomodulatory agent and anti-CD38 monoclonal antibody. Patients received initial step-up doses of 0.06 mg/kg and 0.3 mg/kg administered SC, followed by 1.5 mg/kg SC once-weekly thereafter until disease progression or unacceptable toxicity. Patients who had a CR or better for ≥6 months were eligible to reduce dosing frequency to 1.5 mg/kg SC Q2W until disease progression or unacceptable toxicity. Efficacy population treated at the pivotal study dose in Phase 2 had a median duration of follow-up of 8.8 months at the primary analysis.

‡ ORR was a composite of sCR + CR + VGPR + PR as determined by the IRC assessment using IMWG 2016 criteria.

§ Follow-up analysis included 15 additional patients since the primary analysis.

¶ Efficacy population treated at the pivotal dose in Phase 2.

References: 1. TECVAYLI® (teclistamab injection) Product Monograph. Janssen Inc. August 29, 2024. **2.** Data on file, Janssen Inc.

Johnson&Johnson | 19 Green Belt Drive | Toronto, Ontario | M3C 1L9 | **innovativemedicine.jnj.com/canada**

TECVAYLI (teclistamab) | MEMBER OF INNOVATIVE MEDICINES CANADA | REVIEWED BY PAAB | Johnson & Johnson

Canadian Jurisdiction (*year published*)*	Criteria for Prescribing Ig Replacement Therapy (*summary*)	Dosing Recommendations	Review Criteria for Assessing the Effectiveness of Ig Use
British Columbia (2024)	Prevention of recurrent bacterial infections due to hypogammaglobulinemia associated with hematological malignancies or post-HSCT. **Qualifying Criteria** • Serum IgG must be measured on two separate occasions (at least one sample taken when the patient does not have an active infection, ideally for 4-6 weeks) Baseline serum levels of IgA and IgM should be obtained with the second IgG for assessment of immune recovery Consider pre-existing primary immunodeficiency, if not excluded previously, especially if there is a family history or other non-immunoglobulin deficiency infectious findings Significant hypogammaglobulinemia with serum IgG <5g/L. If paraprotein confounds the serum IgG level (such as in MM), then the indication for starting Ig can exclude the serum IgG level **AND EITHER:** 1. At least one life threatening bacterial infection in the last 12 months (ICU admission) 2. At least two serious bacterial infections in the last 6 months requiring more than standard courses of antibiotics (e.g., hospitalization, intravenous or prolonged antibiotic therapy) **WITH BOTH:** 1. Infections unrelated to chemo/radiotherapy, including neutropenia or mucosal/epithelial toxicity 2. Infections confirmed to be due to encapsulated bacteria and/or are clinically consistent with encapsulated bacteria	Antibiotic therapy may be indicated in addition to Ig therapy. **Loading Dose (IVIg)** - One loading dose of 0.4 g/kg (ABW) in the first month of therapy (in addition to the maintenance dose) is permitted if the serum IgG level is <4 g/L. **Maintenance Dose (IVIg)**- 0.4–0.6g/kg (ABW) every 4 weeks or more frequently, to achieve IgG trough level of at least the lower limit of the age-specific serum IgG reference range initially. Trough levels are to be measured within a week before the next infusion, with target trough IgG levels generally at 7-10 g/L (and/or the minimal dose required for clinical effectiveness). SC administration of Ig should be considered as an alternative to IVIg allowing homecare rather than a medical daycare unit or infusion clinic. **Maintenance Dose (SCIg) -** 0.1-0.15g/kg every week or more frequently, to achieve IgG trough level of at least the lower limit of the age-specific serum IgG reference range initially.	Ig should only be continued or renewed if there is a demonstrated clinical benefit. Documentation of clinical effectiveness is necessary for continuation of Ig therapy. The lowest dose possible that achieves the appropriate clinical outcome for each patient is to be used. The goal of Ig in immune deficiency is to minimize infections, as completely eliminating risk of infections is not a feasible target.

Canadian Jurisdiction (*year published*)*	Criteria for Prescribing Ig Replacement Therapy (*summary*)	Dosing Recommendations	Review Criteria for Assessing the Effectiveness of Ig Use
Prairie Collaborative (Saskatchewan, Manitoba, Alberta) (2022)	Ig replacement is recommended for secondary prevention of recurrent, severe infection due to hypogammaglobulinemia (excluding paraprotein) related to other diseases or medical therapy in patients who have a history of infections. It is not recommended for routine replacement of Ig as primary prophylaxis against infections in the setting of an isolated low IgG level without infection. The decision to use Ig should be made in consultation with a physician with recognized expertise in immunodeficiency disorders. Hypogammaglobulinemia secondary to underlying disease or medical therapy (including HSCT) with all of the following: • Serum IgG less than the lower limit of the reference range on two separate occasions **AND** **At least one of the following:** • One invasive or life-threatening infection (e.g., pneumonia, meningitis, sepsis) in the previous year • Recurrent, severe infections • Clinically active bronchiectasis confirmed by radiology • Assessment by a physician specializing in immunodeficiency indicating a significant antibody defect that would benefit from Ig replacement	**Maintenance:** 0.4 to 0.6 g/kg adjusted body weight IVIg every 4 weeks, or SCIG 0.1-0.15 g/kg (ABW) weekly, modified to achieve an IgG trough level of at least the lower limit of the age-specific serum IgG reference range, or as needed to achieve clinical effectiveness. **Loading:** One additional dose of 0.4 g/kg (ABW) may be given in the first month of therapy if the serum IgG level is markedly reduced. *Chronic suppurative lung disease:* 0.4 to 0.8 g/kg (ABW) IVIg or equivalent SCIg dose may be given if chronic suppurative lung disease is not adequately controlled at an IgG trough level at the lower limit of the age-specific serum IgG reference range. *Disseminated enterovirus infection:* One dose of 2 g/kg (ABW) (IVIg or SCIg) divided over 2 to 5 days at any stage is permitted (in addition to the maintenance dose).	Continued use of Ig should be based on objective measures of effectiveness established at the outset of treatment. The following outcome measures should be recorded: • IgG level every 3 to 6 months; AND • number of infections and hospital admissions for infection If clinical effectiveness has not been achieved, Ig treatment should be discontinued. Cessation of Ig treatment may be possible depending on the status of the underlying disease.

Canadian Jurisdiction (*year published*)*	Criteria for Prescribing Ig Replacement Therapy (*summary*)	Dosing Recommendations	Review Criteria for Assessing the Effectiveness of Ig Use
Ontario (2025)	Hypogammaglobulinemia acquired secondary to hematological malignancies. Ig replacement is recommended for secondary prevention of recurrent, severe infection due to secondary hypogammaglobulinemia (excluding paraprotein) in patients who have a history of infections. It is not recommended for routine replacement of Ig as primary prophylaxis against infections in the setting of an isolated low IgG level without infection. **Qualifying Criteria** • Hypogammaglobulinemia secondary to underlying disease or medical therapy (including HSCT) with all the following: • Serum IgG less than the lower limit of the reference range on two separate occasions **AND** **At least one of the following:** • One invasive or life-threatening infection (e.g., pneumonia, meningitis, sepsis) in the previous year • Recurrent, severe infections • Clinically active bronchiectasis confirmed by radiology • Assessment by a physician specializing in immunodeficiency indicating a significant antibody defect that would benefit from Ig replacement	**Maintenance:** 0.4-0.6 g/kg (ABW) IVIg every 4 weeks, or SCIg 0.1-0.15 g/kg (ABW) weekly, modified to achieve an IgG trough level of at least the lower limit of the age-specific serum IgG reference range, or as needed to achieve clinical effectiveness. **Loading:** One additional dose of 0.4 g/kg (ABW) may be given in the first month of therapy if the serum IgG level is markedly reduced. *Chronic suppurative lung disease:* 0.4-0.8 g/kg (ABW) IVIg or equivalent SCIg dose may be given if chronic suppurative lung disease is not adequately controlled at an IgG trough level at the lower limit of the age-specific serum IgG reference range. *Disseminated enterovirus infection:* One dose of 2 g/kg (ABW) (IVIg or SCIg) divided over 2 to 5 days at any stage is permitted (in addition to the maintenance dose).	**Review Criteria** The following outcome measures should be recorded: • IgG level within 3 to 6 months; and number of infections and hospital admissions for infection • Cessation of Ig treatment may be possible depending on the status of the underlying disease.
Atlantic Provinces (Nova Scotia, New Brunswick, Newfoundland and Labrador, Prince Edward Island) (2022)	Patient has/had recent life-threatening or recurrent clinically significant infection(s) related to low levels of polyclonal Ig.	**IVIg dose:** 0.4-0.7 g/kg every 3 to 4 weeks. **SCIg dose:** 0.1-0.23 g/kg every week.	None.

Canadian Jurisdiction (*year published*)*	Criteria for Prescribing Ig Replacement Therapy (*summary*)	Dosing Recommendations	Review Criteria for Assessing the Effectiveness of Ig Use
Québec (2025)	Secondary hypogammaglobulinemia due to a hematological cancer or its treatment. **Secondary prophylaxis if the following 3 criteria are met:** • IgG <4 g/L OR on a case-by-case basis if IgG is ≥4 g/L and <6 g/L; • Biologically active cancer treatment OR incomplete immune reconstitution; • Severe, unusual, or recurrent infections	**Initial dosage:** • **IVIg dose:** 0.4 to 0.6 g/kg. • IVIg is generally administered every 3 to 4 weeks. **Maintenance dosage:** Adjust to achieve a residual IgG level at least equal to the lower limit of the reference range according to age or based on clinical efficacy. **Subcutaneous Immunoglobulin (IgSC) and Facilitated Subcutaneous Immune Globulin** **Initial dosage:** 0.1 to 0.2 g/kg. IgSC can be administered daily, weekly, or every two weeks. Facilitated IgSC can be administered weekly initially, then the dose should be gradually adjusted to achieve administration every 3 to 4 weeks. **Maintenance dosage:** Adjust to achieve a residual IgG level at least equal to the lower limit of the reference range according to age or based on clinical efficacy. **Note:** In the case of a severe or life-threatening infection, the initial dose may be higher.	**Duration:** until remission OR immune reconstitution, depending on the clinical situation. **Discontinuation:** yes, after confirmation of remission OR immune reconstitution, depending on the clinical situation.

Table 2. Comparison of approved jurisdictional criteria to access immunoglobulin replacement therapy (IgRT) in the setting of hypoammaglobulinemia secondary to hematologic malignancies within Canadian provinces and territories.[15-19] Prescribers are required to include the indication for IgRT on forms that are reviewed in accordance with provincial policy to ensure Ig request compliance with Ministry of Health-endorsed criteria within each jurisdiction. The territories have not yet endorsed the use of a specific IgRT criteria document; *courtesy of Oksana Prokopchuk-Gauk, MD, FRCPC, DRCPSC, Kathryn Webert, MD, MSc, FRCPC, and Jennifer Grossman, MD, FRCPC.*

*The most current versions of the criteria for prescribing IgRT are included in this summary. However, as documents may periodically be updated, prescribers should confirm the most current version of criteria for accessing IgRT within their jurisdictions when prescribing Ig for patient care.

Abbreviations: ABW: adjusted body weight; **HSCT:** hematopoietic stem cell transplantation; **ICU:** intensive care unit; **Ig:** immunoglobulin; **IVIg:** intravenous Ig; **MM:** multiple myeloma; **SCIg:** subcutaneous Ig.

International Criteria (*year published*)*	Criteria for Prescribing Ig Replacement Therapy (*summary*)	Dosing Recommendations	Review Criteria for Assessing the Effectiveness of Ig Use
Australian National Blood Authority (NBA) (2025)	Prevention of recurrent bacterial infections due to hypogammaglobulinemia associated with hematological malignancies or post-HSCT. **Qualifying Criteria** • Serum IgG to be measured on two separate occasions (at least one sample taken when the patient does not have an active infection). Baseline serum levels of IgA and IgM should be provided to allow assessment of immune recovery at review. • Significant hypogammaglobulinemia with serum IgG <4 g/L (excluding paraprotein) regardless of the frequency and severity of infections **OR** • Serum IgG (excluding paraprotein) >4 g/L but less than the lower limit of the age-related reference range with at least one life threatening infection in the last 12 months **OR** • Serum IgG (excluding paraprotein) >4 g/L but less than the lower limit of the age-related reference range with at least 2 serious infections in the last 6 months requiring more than standard courses of antibiotics (e.g., hospitalization, intravenous or prolonged antibiotic therapy) Antibiotic therapy may be indicated in addition to Immunoglobulin therapy.	**Loading Dose (IVIg and SCIg):** one loading dose of 0.4 g/kg in the first month of therapy (in addition to the maintenance dose) is permitted if the serum IgG level is <4 g/L. **Disseminated Enterovirus Dose (IVIg and SCIg):** one dose of 2 g/kg at any stage is permitted (in addition to the maintenance dose) in the management of disseminated enterovirus infection. **Maintenance Dose (IVIg):** 0.4–0.6g/kg every 4 weeks or more frequently, to achieve IgG trough level of at least the lower limit of the age-specific serum IgG reference range. More frequent dosing to achieve IgG trough level of up to 9 g/L is permitted if chronic suppurative lung disease is not adequately controlled at an IgG trough level at the lower limit of the age-specific serum IgG reference range. A total dose of up to 1 g/kg may be given over any 4-week period. **Maintenance Dose (SCIg):** 0.1-0.15 g/kg every week or more frequently, to achieve IgG trough level of at least the lower limit of the age-specific serum IgG reference range. More frequent dosing to achieve IgG trough level of up to 9 g/L is permitted if chronic suppurative lung disease is not adequately controlled at an IgG trough level at the lower limit of the age-specific serum IgG reference range. A total dose of up to 1 g/kg may be given over any 4-week period. **Supplementary Dose (IVIg and SCIg):** One additional dose of 0.4 g/kg is permitted at any stage (in addition to the maintenance dose) if the serum IgG level is <4 g/L. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient.	Initial review is required within 6 months by any specialist with ongoing reviews at least annually to assess clinical benefit. In principle, Ig should be continued or renewed only if there is a demonstrated clinical benefit; therefore, documentation of clinical effectiveness is necessary for continuation of Ig therapy. Clinical effectiveness of Ig therapy may be assessed by monitoring of serum immunoglobulin levels (IgG, IgA, and IgM) and any history of infection. There should be regular consideration of a trial period of cessation of Ig (at least every 12 months) for the purposes of immunological evaluation unless medically contraindicated on safety grounds (such as neutropenia, immunosuppressant medication, active bronchiectasis, and/or suppurative lung disease) or severe hypogammaglobulinemia persists where no significant improvement has occurred in the underlying condition. Trial cessation is best commenced in September or October.

International Criteria (*year published*)*	Criteria for Prescribing Ig Replacement Therapy (*summary*)	Dosing Recommendations	Review Criteria for Assessing the Effectiveness of Ig Use
National Health Service Blood and Transplant (NHSBT), UK (2025)	**Qualifying Criteria** • Underlying cause of hypogammaglobulinemia cannot be reversed, or reversal is contraindicated. **OR** • Hypogammaglobulinemia associated with drugs, including emerging bispecific antibody therapies, therapeutic monoclonals targeted at B cells and plasma cells (rituximab and other anti-CD20/CD19 agents, daratumumab, etc.) post-HSCT, NHL, CLL, MM or other relevant B-cell malignancy confirmed by hematologist **AND** • Recurrent or severe bacterial infection despite continuous oral antibiotic therapy for 6 months • IgG <4 g/L (excluding paraprotein) • Documented failure of serum antibody response to unconjugated pneumococcal or other polysaccharide vaccine challenge **Notes:** • In patients developing hypogammaglobulinemia associated with B-cell aplasia as a consequence of CAR T-cells targeted against B cell or plasma cell antigens, the prophylactic use of Ig in the absence of a burden of severe infections and vaccine challenge may be appropriate • Use of Ig post-CAR T-cell therapy in B-ALL: because of the severity of B-cell aplasia and the longer time required for reconstitution, it is anticipated that virtually all patients (children and adults) with B-ALL will initially require Ig replacement following CAR T-cell therapy. As with the use of Ig post-CAR T-cell therapy in B-cell lymphoma, continued use of IVIg should be reviewed at regular intervals based on B-cell recovery, serum immunoglobulins and burden of infection • Use of Ig post-CAR T-cell therapy in B-cell lymphoma: The need for Ig replacement in patients receiving CAR T-cell therapy for B-cell lymphoma is variable, ranging between 31% and 64% in published studies, highlighting faster B-cell recovery in this group in contrast to patients with B-ALL • Use of Ig at inception of bispecific antibody treatment in patients with myeloma and B-cell lymphoma: many patients in these disease groups will have a low serum IgG at baseline due to previous chemo-immunotherapy, including CD20 and CD38-depleting agents. The prophylactic use of Ig would be appropriate in patients with a serum IgG <4g/L at the time of commencement of a bispecific antibody	0.4–0.6 g/kg/month modified to achieve an IgG trough level of at least the lower limit of the age-specific serum IgG reference range	6 monthly reviews (compared to baseline) • Raised trough IgG level • Reduction in number of infections • Reduction in number of treatment courses of • antibiotics • Reduction in number of days in hospital

Table 3. Comparison of criteria to access immunogbulin replacement therapy (IgRT) in the setting of hypoammaglobulinemia secondary to hematologic malignancies from selected countries where Ig products are funded through public healthcare arrangements.[20,21] Prescribers are required to comply with these criteria to access IgRT within their jurisdictions; *courtesy of Oksana Prokopchuk-Gauk, MD, FRCPC, DRCPSC, Kathryn Webert, MD, MSc, FRCPC, and Jennifer Grossman, MD, FRCPC*.

Abbreviations: B-ALL: B-cell acute lymphoblastic leukemia; **CAR-T:** chimeric antigen receptor T cell; **CLL:** chronic lymphocytic leukemia; **HSCT:** hematopoietic stem cell transplantation; **Ig:** immunoglobulin; **IVIg:** intravenous Ig; **SCIg**: subcutaneous Ig; **MM:** multiple myeloma; **NHL:** non-Hodgkin lymphoma

In Canada, Ig products are procured by Canadian Blood Services for all provinces and territories except Québec, which receives products from Hema-Québec. A Request for Proposal process is executed to determine Ig supply vendors for defined periods, to ensure the lowest feasible product cost. IgRT is funded through provincial/territorial tax dollars as a part of the Canadian universal healthcare system. Thus, IgRT utilization appropriateness is carefully monitored within Canadian provinces and territories to ensure accountability.[22] All Ig products are expected to meet utilization appropriateness criteria as defined by respective regional guidelines endorsed by provincial/territorial Ministries of Health.[23] IgRT preparations currently available in Canada are considered equivalent in terms of their potency and efficacy based on concentration, regardless of indications listed within the approved product monograph.[24] The list of currently available Ig products from Canadian Blood Services is listed in the **EFormulary**, and products available in Québec are listed on the **Héma-Québec website**.

Potential Adverse Reactions to Ig

As human blood product concentrates, IgRT products may cause potential adverse transfusion reactions. Expressed informed consent must be obtained by authorized prescribers prior to the administration of IgRT products.

Infection transmission from Ig products is considered theoretical, given the extensive donor screening, testing, and pathogen reduction manufacturing processes. Significant non-infectious risks of Ig must be discussed with the patient as a part of the informed consent process. Risks of IVIg administration and rates occurrence include[25]:

- Non-serious flu-like symptoms (chills; headache; chest, back, or abdominal pain; nausea/vomiting) and hypotension or hypertension in up to 1:5 recipients[26];
- Clinically significant red blood cell hemolysis in up to 1:5 non-group O recipients (due to passive anti-A and anti-B), occurring with within 10 days of IVIg infusion[27];
- Thromboembolic events in up to 1:100 recipients[28];
- Aseptic meningitis in 1:1500 recipients[29]; and
- Anaphylaxis in less than 1:1000 recipients

The risk of local site injection reactions is more common with SCIg (pain, local site irritation). Systemic reactions are less common overall in comparison to IVIg, making SCIg a safer option from the perspective of adverse reaction risk.

Isolated reactions may be idiosyncratic, associated with the blend of donor proteins within a particular product lot number, which do not recur with exposure to a different lot number of the same brand. Recurrent reactions to the same Ig brand may be associated with non-Ig components of the product and warrant trial of a brand switch. Consultation with the local Transfusion Medicine Physician is recommended to discuss product options if serious or recurrent reactions to Ig develop.

SHG and IgRT in Specific Hematologic Malignancies

Multiple Myeloma (MM)

Patients with MM may have SHG at the time of diagnosis as a consequence of their disease. However, in the setting of relapsed or refractory MM, there is a further increased risk of SHG due to both the underlying MM pathology and therapeutic exposures.[30]

Bispecific antibody and CAR T-cell therapies are now available to patients who have received at least 3 prior lines of treatment. Infections are common with bispecific antibody therapy, with rates reported to be 32–76% (any grade), and severe Grade 3–4 infections reported in up to 45% of cases.[31] This infection risk may be related to the bispecific antibody dose and frequency, as dose reductions appear to confer a reduction in infectious risk.[32]

The overall infection risk in patients receiving CAR T-cell therapy for MM was comparable to that of bispecific antibody therapy, with rates of 9–70% reported (any grade); however, the risk of severe grade 3 or higher infections was lower, reported in up to 30% of cases.[4] Interestingly, IgG levels were not measured in all CAR T studies; in the

two studies where IgG levels were measured, SHG with IgG levels under 4 g/L was observed in up to 23.5% of patients.[33,34]

The preventative role of Ig in patients undergoing MM therapy is an area of ongoing investigation. It is prudent to check IgG levels at diagnosis (excluding the monoclonal protein total). Due to the high infection risk with bispecific antibody therapy, current consensus guidelines recommend routine monitoring of IgG levels for SHG. It would be reasonable to check IgG levels every 6 months and whenever significant or recurrent infections occur.[1] Initiation of prophylactic IgRT replacement may be considered if serum IgG levels are under 4 g/L during treatment and thereafter, or in the setting of severe or recurrent infections with higher IgG concentrations.[31] A dose of 0.4 g/kg IVIg administered every 4 weeks[4] or 0.1 g/kg SCIg weekly may be considered with the intent to achieve a minimum effective dose.

Chronic Lymphocytic Leukemia (CLL)

SHG is a well-known complication of CLL in the context of this underlying B-cell disease, with evaluation of baseline serum Ig levels recommended at diagnosis as a part of routine patient work-up.[35] Treatments, including immunosuppressive regimens and B cell-targeted therapies have the potential to exacerbate the degree and duration of SHG; thus, experts have recommended that clinical follow-up of infection history and serum Ig level evaluation should occur at a minimum every 6 months.[36]

There is a strong body of literature demonstrating that IgRT confers a decrease in the frequency of bacterial infections, including major bacterial infections in patients with CLL and SHG. However, no survival benefit with IVIg use has been demonstrated.[37] Clinical practice guideline recommendations vary, though there is consensus to initiate IgRT in patients with SHG with repeated infections at immune replacement doses, including 0.4 g/kg IVIg or 0.1 g/kg SCIg; prophylactic use of IgG to prevent primary infection is not endorsed.[38,39]

Lymphoma

The prevalence of SHG appears to be lower in patients at the time of B-cell lymphoma diagnosis than in patients with MM and CLL. Thus, confirming patient serum Ig levels at the time of lymphoma diagnosis is appropriate to establish a baseline. The risk of SHG is known to increase with B-cell-targeted therapy, including rituximab.[1] SHG has been observed in nearly 40% of patients after a rituximab-based therapy; however, only a minority are of clinical significance (non-neutropenic infections requiring IgRT).[40] Variability in definitions of SHG, inconsistencies in the measurement frequency of IgG levels among lymphoma trial participants, and the evolution of lymphoma diagnosis and treatment has led to challenges in the evaluation and management of SHG in this population.

Management of more intensive diffuse large B-cell lymphoma may include autologous stem cell transplantation, bispecific antibody therapy, and CAR T-cell therapies. More intensive treatments like bispecific antibody therapy and CAR T-cell therapies may increase the risk of SHG in patients with relapsed or refractory disease, but its incidence and duration can be variable.[41,42]

Presently, there is no definitive role for prophylactic IgRT during lymphoma treatment, regardless of the underlying diagnosis and measured serum IgG levels, in the absence of severe or recurrent infections.

Recommendations regarding the frequency of Ig measurement in patients receiving lymphoma treatment are not specific, though it may be reasonable to consider evaluating serum IgG levels every 6 months or as required based on recurrent or severe infections.[1] A precise management strategy for SHG in the context of lymphoma treatment has not yet been clearly defined due to the lack of randomized, controlled trial data.[1,5] Following CAR T-cell therapy, it is reasonable to consider IgRT in adults with serious or recurrent infections with encapsulated organisms and IgG levels under 4 g/L.[42] An immune supportive dose of 0.4 g/kg IVIg or 0.1 g/kg SCIg may be initiated in this context. At this time, no clear role for prophylactic IgRT has been defined in adult CAR T-cell therapy recipients who have not developed an infection.

Hematopoietic Stem Cell Transplantation (HSCT)

To date, a definitive clinical benefit of Ig replacement for prevention against bacterial infections in the setting of autologous and allogeneic bone marrow transplantation has not been demonstrated. Establishing a pre-transplant IgG level is prudent to establish a baseline. Monitoring for infection is essential throughout the patient's treatment course.

In 2018, Canadian and American HSCT experts collaborated to develop five Choosing Wisely recommendations with the aim of reducing unnecessary healthcare resource utilization while providing optimal patient care. Given the absence of high-quality evidence demonstrating infection prevention and overall survival, plus commentary that IgRT may predispose patients to a higher risk of complications and adverse effects, the recommendation "*don't routinely give Ig replacement in adult HSCT recipients in the absence of recurrent infections regardless of Ig level*" was included.[43]

European bone marrow transplant best practice recommendations reaffirm that late infection prevention (more than 100 days following transplantation) against encapsulated bacterial infection includes oral antibiotic prophylaxis as a first-line strategy. Initiation of IgRT may also be considered at an immune supportive dose in patients with serum IgG levels of less than 4 g/L. Finally, vaccination should be initiated with immune recovery.[44]

A Proposed Approach to SHG Management in Hematologic Malignancies

The decision to initiate Ig prophylaxis in patients with SHG with hematologic malignancies is complex and multifactorial. We have adapted a framework recently proposed by experts[14], based on current literature (with an acknowledgement of existing limitations)[27], as summarized in **Figure 1**. Shared decision-making between patients and healthcare providers remains an essential component of determining the right time to initiate Ig replacement therapy, balancing the risks and benefits of this treatment, relative to potential alternative strategies for infection prevention, in the context of potential global Ig supply limitations.

Future Ig Sustainability

In Canada, the demand for Ig is expected to increase by approximately 10% each year for the next 5 years. SHG is expected to be the fastest-growing area for immunoglobulin use in Canada, with the potential for growth for this indication estimated to be closer to 15% over the next 5 years. This growth is mostly due to factors such as the increased availability and use of new immunosuppressant therapies, the increasing prevalence of diseases such as leukemias, MM, and lymphoma, and the fact that patients who may require IgRT are living longer with disease due to improvements in treatments and supportive care.[45]

This rapid growth in demand for Ig products is also seen internationally, in both developed and developing countries, leading to global shortages and related impacts on pricing. This has prompted many jurisdictions to significantly increase the collection of plasma, the critical material from which Ig drugs are made, to meet population needs. In Canada, Canadian Blood Services and Héma-Québec are exploring ways to expand and accelerate plasma collection and promote immunoglobulin production within domestic borders.

While Canadian patients' needs for IgRT are currently being met, the ongoing global shortage of Ig has raised concerns about sustainability and the possibility of a Canadian Ig shortage. Because of this, the *Canadian National Advisory Committee for Blood and Blood Products*, through the support of Health Canada and provincial/ territorial Ministries of Health, recently developed the *National Plan for the Management of Shortages of Immunoglobulin Products (The Ig Plan)*.[46] The specific purpose of the national Ig Plan is to maximize the effectiveness of a response to any crisis that impacts the adequacy of the overall Ig supply in Canada. The Ig Plan acknowledges that difficult decisions will need to be made about allocating Ig product in the event of a shortage. It also emphasizes the use of alternative therapies to Ig, where applicable. Criteria to guide clinical decisions and triage of Ig products, as well as an ethical framework, are provided to guide decision making and to assist with doing as little harm as possible.

Additional high-quality studies that utilize standard definitions for SHG and severe or recurrent infection are needed in the setting of hematologic malignancies to better understand the role of IgRT for primary or secondary infection prevention. Currently, there are limited data to inform when IgRT should be started, when it can be stopped, how it should be dosed, and the role of alternatives like antibiotic use for infection prevention. The RATIONAL platform trial at several sites in Canada is aimed at helping answer some of these questions. This investigator-initiated, international (Australia, New Zealand, Canada), Phase II/III randomized controlled trial has three domains: the START domain will compare prophylactic antibiotics to standard dose IgRT for patients eligible to start IgRT; the STOP



Figure 1. A proposed approach for evaluating SHG in hematologic malignancies, based on presented evidence; *adapted from Pendergrast et al., 2021.*[27]

Abbreviations: CAR-T: chimeric antigen receptor T cell; **Ig:** immunoglobulin; **IgRT:** Ig replacement therapy.

domain will compare stopping IgRT with either prophylactic antibiotics or antibiotics on demand, to continuing standard dose IgRT; and the DOSE domain will compare low dose and standard dose IgRT.[47]

Summary

The decision to initiate IgRT in patients with hematologic malignancies is complex and must consider both patient and healthcare system impacts. To obtain IgRT, clinicians in provinces and territories are required to comply with the clinical criteria for Ig, endorsed within their regional jurisdictions. Current evidence supports close patient monitoring and IgRT initiation at immune supportive doses in the setting of severe or recurrent infections with documented significantly reduced IgG levels. SCIg is an important IgRT option that is more convenient and less resource-intensive. Additional guidance is needed to better understand when to decrease or stop IgRT. It is essential to maintain stringent Ig use, as current product utilization trends will be unsustainable into the future. Exploration of alternatives to Ig for infection prevention in the setting of SHG must be prioritized.

Special thanks to Dr. Vincent Laroche, Hematologist from CHU de Québec - Université Laval, for providing the English translation of the Québec criteria for optimal use of immunoglobulin.

Correspondence

Oksana Prokopchuk-Gauk, MD, FRCPC, DRCPSC
Email : oksana.prokopchuk-gauk@saskhealthauthority.ca

Financial Disclosures:

O.P.G.: Member of the National Advisory Committee on Blood and Blood Products; **Honoraria:** Canadian Blood Services and Octapharma.
K.W.: Employee of Canadian Blood Services.
J.G.: None declared.

References

1. Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. J Allergy Clin Immunol. 2022;1949:1525-60.
2. Monahan R, Otani IM, Lehman HK, Mustafa SS. A second look at secondary hypogammaglobulinemia. Ann Allergy Asthma Immunol. 2025;134:269–278
3. Dhalla F, Misbah SA. Secondary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2015;15:505-13.
4. Ludwig H, Terpos E, van de Donk N, Mateos M, Moreau P, Dimopoulos M, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24(6):e255-e269.
5. Wat J, and Barmettler S. Hypogammaglobulinemia after Chimeric Antigen Receptor (CAR) T-cell therapy: characteristics, management, and future directions. J Allergy Clin Immunol Pract. 2022;10(2):460–466. doi:10.1016/j.jaip.2021.10.037.
6. Mikulic M. Immunoglobulin consumption in select countries in 2017. Statista. [Internet]. https://www.statista.com/statistics/1055466/immunoglobulin-consumption-in-select-countries/ Accessed June 15, 2025.
7. Protecting Access to Immune Globulins for Canadians. Health Canada. 2018-05-16. https://www.canada.ca/en/health-canada/programs/expert-panel-immune-globulin-product-supply-related-impacts-canada/protecting-access-immune-globulins-canadians.html Accessed June 15, 2025.
8. Jeffrey Modell Foundation "10 Warning Signs of Primary Immune Deficiency in Adults" https://info4pi.org/library/educational-materials/. Accessed July 21, 2025.
9. Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2012;130(3 suppl):S1-24.
10. Kainulainen L, Vuorinen T, Rantakokko-Jalava K, Osterback R, Ruuskanen O. Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 2010;126(1):120-6.
11. Ritchie B, Martins KJB, Tran DT, Blain H, Richer L, Klarenback SW. Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study. Allergy Asthma Clin Immunol. 2022;18(1):99. doi: 10.1186/s13223-022-00735-6.
12. McQuilten ZK, Weinkove R, Thao LTP, Crispin P, Degelia A, Dendle C, et al. Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy. Blood Adv. 2024;8(7):1787-95.

13. Mankaruious S, lee M, Fischer S, Pyun KH, Ochs HD, Oxelius VA, et al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med. 1988;112(5):534-40.
14. Otani IM and Ballow M. If and when to consider prophylactic immunoglobulin replacement therapy in secondary hypogammaglobulinemia. J Allergy Clin Immunol Pract. 2025;13(3):511-21.
15. British Columbia Provincial Blood Coordinating Office. Immunodeficiency Ig Resources. Secondary Immunodeficiency. Accessed on June 24, 2025 at https://www.pbco.ca/index.php/programs/immunodeficiency/secondary-immunodeficiency.
16. Prairie Collaborative Immune Globulin Utilization Management Framework Project. Criteria for the clinical use of immune globulin. Second Edition. Alberta Ministry of Health, Shared Health Manitoba, and Saskatchewan Ministry of Health; 2022. Accessed on June 24, 2025 at https://ihe.ca/public/uploaded/Prairie%20Ig%20Final%20Guideline%20 09.02.22.pdf.
17. Ontario Immune Globulin Utilization Management. Version 5.0. Ontario Regional Blood Coordinating Network (ORBCoN). 2025 Accessed on June 24, 2025 at https://transfusionontario.org/en/category/ivig-scig/utilization-management-guidelines/ .
18. Atlantic Blood Utilization Strategy Working Group (2021) Atlantic Clinical Indications and Criteria for Intravenous and Subcutaneous Immunoglobulin (IVIG/SCIG) Version 2.0 Halifax, NS. (IVIG/SCIG). April 2022. Accessed on June 24, 2025 at https://www.gov.nl.ca/hcs/files/Atlantic-Clinical-Indications-and-Criteria-for-Intravenous-and-Subcutaneous-Immunoglobulin-IVIG-SCIG.pdf .
19. Usage optimal des immunoglobulins. Institut national d'excellence en santé et en services sociaux Québec. (2025). Accessed on July 24, 2025 at https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/usage-optimal-des-immunoglobulines.html
20. Clinical Commissioning Policy for the use of therapeutic immunoglobulin (Ig) England (2025). Accessed on June 24, 2025 at https://www.england.nhs.uk/wp-content/uploads/2021/12/ccp-for-the-use-of-therapeutic-immunoglobulin-england-2025.pdf
21. Criteria for immunoglobulin products. National Blood Authority, Australia. Accessed on June 24, 2025 at https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/criteria-immunoglobulin-products.
22. Clinical Guide to Transfusion – Chapter 1. https://professionaleducation.blood.ca/en/transfusion/clinical-guide/vein-vein-summary-blood-system-canada Accessed June 15, 2025.
23. NAC Ig Utilization Statement. https://nacblood.ca/en/resource/immunoglobulin-utilization-statement Accessed June 15, 2025.
24. NAC Statement on Clinical Equivalency of Select Fractionated Plasma Protein Products. https://nacblood.ca/en/resource/nac-statement-clinical-equivalency-select-fractionated-plasma-protein-products Accessed June 15, 2025
25. Callum JL, et al. Bloody Easy 5.1 (2023). Ontario Regional Blood Coordinating Network. p. 110. https://transfusionontario.org/en/bloody-easy-5-blood-transfusions-blood-alternatives-and-transfusion-reactions-a-guide-to-transfusion-medicine-fifth-edition-handbook/ Accessed June 16, 2025.
26. Souayah N, Hasan A, Khan HMR, Yacoub HA, Jafri M. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders. J Clin Neuromuscul Dis. 2011;12(Suppl 4):S1-S10.
27. Pendergrast J, Armali C, Callum J, Cserti-Gazdewich C, Jiwajee A, Lieverman L, et al. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis. Transfusion. 2021;61(4):1053-1063.
28. Ammann EM, Jones MP, Link BK, Carnahan RM, Winiecki SK, Torner JC, et al. Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. Blood. 2016;127(2):200-207.
29. Bharath V, Eckert K, Kang M, Chin-Yee IH, Hsia CC. Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis; a retrospective review at a single tertiary care centre. Transfusion. 2015;55(11):2597-2605.
30. Giralt S, Jolles S, Kerre T, Lazarus HM, Mustafa SS, Papanicolaou GA, et al. Recommendations for management of secondary antibody deficiency in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23(10)719-32.
31. Rodríguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, Perez-Larraya JG, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25(5):e205-e216.
32. Usmani SZ, Karlin L, Benboubker L, Nahi H, San-Miguel J, Trancucci D, et al. Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study. Proc Am Soc Clin Oncol 2023;41(suppl):8034.
33. Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16.
34. Chen W, Fu C, Fang B, Liang A, Xia Z, He Y, et al. Phase II study of fully human BCMA-targeting CAR-T cells (zevorcabtagene autoleucel) in patients with relapsed/refractory multiple myeloma. Blood. 2022;138(suppl 1):4564–65.

35. Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v78-84.
36. Lachance S, Christofides AL, Lee JK, Sehn LH, Ritchie BC, Shustik C, et al. A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia. Curr Oncol. 2016;23(1):42-51.
37. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009;50(5):764-72.
38. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
39. Walewska R, Parry-Jones N, Eyre TA, Follows G, Martinez-Calle N, McCarthy H, et al. Guideline for the treatment of chronic lymphocytic leukaemia. Br J Haematol. 2022;197(5):544-557.
40. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13(2):106-11.
41. Gerhard GM and von Keudell G. Bispecific antibody therapy for lymphoma. Best Practice & Research Clinical Haematology. 2024;37(4):101598.
42. Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33(3):259-75.
43. Bhella S, Majhail NS, Betcher J, Costa LJ, Daly A, Dandoy CE, et al. Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018;24(5);909-13.
44. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies. Sureda A, et al (Editors). Springer Nature Switzerland AG. 2024. p. 317. https://www.ebmt.org/education/ebmt-handbook
45. An ZY, Fu H, He Y, Zhu X, Huang Q, Wu J, et al. Projected global trends in hematological malignancies: incidence, mortality, and disability-adjusted life years from 2020 to 2030. Blood. 2023;142(Supplement 1):3810.
46. National Advisory Committee of Blood and Blood Products. The National Plan for Management of Shortages of Immunoglobulin (Ig) Products. 2024. Accessed on June 25, 2025 at https://nacblood.ca/en/blood-shortage.
47. Wood EM, Chai KL, Reynolds J, Griffiths J, Beaton B, Callum J, et al. Optimizing immunoglobulin replacement therapy for patients with B-cell malignancies and hypogammaglobulinemia: the investigator-initiated, international, randomized phase II/III rational platform trial, and the rationalise (stop IGRT) domain. Blood. 2023;142(Supplement 1):1295.

Canadian Hematology Today
Science for the Real World

canadianhematologytoday.com

Canadian Hematology Today is published three times per year in English and French. (ISSN 2816-5152) under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license by Catalytic Health in Toronto, Ontario, Canada.

Pr casgevy®
(exagamglogene autotemcel)
suspension for IV infusion

THE POWER OF PRECISION



ONE GENE. ONE EDIT. ONE TIME.*

CASGEVY® (exagamglogene autotemcel) is an autologous genome edited hematopoietic stem cell-based therapy indicated for the treatment of patients aged 12 years and older with:

- sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs); OR
- transfusion-dependent β-thalassemia (TDT)

Scan here or visit CASGEVY.ca to learn more:

Please consult the Product Monograph at https://pi.vrtx.com/files/Canadapm_casgevy_en.pdf for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use. The CASGEVY Product Monograph is also available by calling Vertex at 1-877-634-8789.

* A search spanning the human genome identified off-target editing at a single variant site. The site is located in an intron of a gene not expressed in hematopoietic cells, so no ill effects are expected.

Reference: Current authorized CASGEVY® Product Monograph. Vertex Pharmaceuticals (Canada) Incorporated.

VERTEX®

Register for future digital and print issues by visiting us at catalytichealth.com/cht

Looking for more?
All back issues are available online at canadianhematologytoday.com